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Abstract 
 
Prostaglandin F2α (PGF2α) is a myometrial stimulant, both PGF2α and its receptor are 
reported to increase towards parturition. With high PGF2α levels correlating with pre-term 
birth, especially those caused by infection. The mechanism by which PGF2α exerts its affects 
on uterine excitation-contraction coupling is unknown.  
The aim of this work was to describe the relationship between force and [Ca2+]i in pregnant 
rat myometrium and the effects of PGF2α on this relationship. The mechanism by which 
PGF2α exerts its affects was also investigated, focused on the role of Ca
2+ entry mechanisms. 
PGF2α was examined on both longitudinal strips and isolated myocytes from pregnant Wistar 
rats. Strips were loaded with the Ca2+ sensitive indicator Indo-1AM and simultaneous 
recording of [Ca2+]i and force were made using a photometric system combined with force 
measurements, at  a sampling rate of 1KHz to get good temporal resolution. Cells were 
isolated using Liberase Blendzyme 3, loaded with Fluo-4AM, and [Ca2+]i recorded using a 
Nipkow Disk based confocal imaging system. 
Pregnant myometrial tissue gave three contractility patterns in control conditions; two 
spontaneously active, giving either irregular contractions, or smooth phasic contractions, 
while the third was not spontaneously active but responsive to high-K+ stimulation. All 
contractions were preceded by a rise in [Ca2+]i which was dependent upon Ca
2+ entry 
through VOCC, while synchronisation was dependent upon gap junctions. 
PGF2α increased myometrial contractility. In spontaneous tissue there were two responses; 
firstly an increase in amplitude, duration and frequency of phasic contraction while the 
second resulted in a tonic-like contraction which lasted for the duration of agonist 
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application. On quiescent tissue, PGF2α resulted in the imitation of spontaneous activity, 
which ceased upon removal of the agonist. [Ca2+]i mirrored force in respect to frequency 
and duration, but PGF2α did not increase the amplitude of Ca
2+ transient above that seen 
under normal spontaneous activity. The increase in amplitude of force induced by PGF2α is 
caused by an increase in the frequency of Ca2+ spikes within the Ca2+ spike burst.  
PGF2α resulted in the oscillatory release of Ca
2+ from the SR in the form of propagating Ca2+ 
waves, initiated at one end of the cell. Re-admission of external Ca2+ resulted in activation of 
a nifedipine-resistance Ca2+ influx sensitive to La3+, which suggests that the stimulant action 
of PGF2α is associated with activation of a Ca
2+-release Ca2+-entry coupling mechanism 
leading to opening of a SOCE pathway. In addition to this PGF2α increase both force and 
[Ca2+]i when applied in the presence of CPA and nifedipine, suggesting that PGF2α also works 
in part through a receptor operated and / or non-selective cation channels. 
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Abbreviations 
 
[   ]     Concentration 
0Ca     Zero calcium 
[Ca2+]i     Cytosolic calcium concentration 
18-β-GA    18-β-glycyrrhetinic acid 
ADP     Adenosine diphosphate 
AM     acetoxymethyl 
ATP     Adenosine triphosphate 
BKCa     Large conductance potassium channel 
˚C     Degrees celcius 
Ca2+     Calcium  
CCE     Capacitative calcium entry 
CCh     Carbachol 
Cl-     Chloride 
ClCa     Calcium activated chloride channel 
CPA     Cyclopiazonic acid 
DAG     Diacylglycerol 
DMSO     Dimethyl sulfoxide 
EGTA     Ethylene glycol tetraacetic acid 
ER     Endoplasmic reticulum 
FP     Prostaglandin F2α receptor 
Gd3+     Gadolinium 
GPCR     G-protein coupled receptor 
HBSS     Hank’s balanced salt solution 
HEPES     4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid ) 
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High-K+    High potassium saline solution  
ICRAC     Calcium release activated calcium current 
IK     intermediate potassium channels 
IP3     inositol 1,4,5-trisphosphate 
IP3R     inositol 1,4,5-trisphosphate receptor 
ISOC     Store operated current 
I.Q.R     Interquartile range 
K+     Potassium 
KATP     ATP-sensitive potassium channel 
KB     Kraft-Brühe 
KCa     Calcium activated potassium channel 
La3+     Lanthanum 
Mg2+     Magnesium 
MLC20     Myosin light chain 20 
MLC20-P    Phosphorylated myosin light chain 20 
MLCK     Myosin light chain kinase 
MLCP     Myosin light chain phosphatase 
N.A.     Numerical aperture 
Na+     Sodium 
NSCC     Non-selective cation channel 
NSCE     Non-selective cation entry 
PG     Prostaglandin 
PGF2α     Prostaglandin F2α 
PGDH     Prostaglandin dehdrogenase 
PDHS     prostaglandin endoperoxide H synthase 
PIP2     Phosphatidylinositol 4,5-bisphosphate 
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PKA     Protein kinase A 
PKC     Protein kinase C 
PLC     Phospholipase C 
PSS     Physiological saline solution 
RNAi     Small interfering RNA 
ROC     Receptor operated calcium channel 
ROCE     Receptor operated calcium entry 
RyR     Ryanodine receptor 
S.E.M.     Standard error of the mean 
SERCA     The sarco / endoplasmic reticulum Ca2+-ATPase   
SK     Small potassium channel 
SOCC     Store operated calcium channel 
SOCE     Store operated calcium entry 
TRP     Transient receptor potential 
SR      Sarcoplasmic reticulum 
VOCC     Voltage operated calcium channels 
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Chapter 1 
General introduction 
 
1.1   The Uterus 
The uterus is the pivotal organ responsible for reproduction, it is responsible for the 
implantation of the fertilised embryo, where it then sustains the growing foetus and at term 
the myometrium becomes active in order to expel the foetus. The human uterus is a pear 
shaped organ, around 6-8cm long in the non-pregnant state, and consists of three layers; 
the serosa, endometrium, and the smooth muscle layer the myometrium. Despite the big 
difference between the human and Wistar rat (Rattus norvegicus) in gross anatomy, at the 
myometrial level they are remarkably similar. The human uterus is a simplex, consisting of 
one single organ, while the uterus of the Wistar rat along with other rodents and primitive 
mammals is duplex. As such they possess two uterine horns, each leading from an ovary to 
the vagina, allowing for multiple offspring (Figure 1.1.a). 
 
1.1.1   The myometrium 
The myometrium is the smooth muscle potion of the uterus is composed of both 
longitudinal and circular smooth muscle layers. The longitudinal layer consists of bundles of 
smooth muscle cells that are orientated parallel to the long axis of the uterus, while the 
circular layer is arranged concentrically to the longitudinal axis, next to the endometrium 
(Figure 1.1b) They have very different physiological and pharmacological characteristic, in 
regards to their electrophysiological and mechanical properties, especially in rat. These  
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differences are apparent during gestation, towards parturition characteristics of the two 
layers become increasingly similar. 
Smooth muscle cells of the myometrium are long, and spindle shaped, whose size is 
dependent upon pregnancy state and the stage of gestation. It is generally agreed that they 
are around 5-10 μm in diameter and 300-600 μm in length, although this is dependent on 
the state of the cell; contracted cells are shorter, but thicker in the middle, whereas relaxed 
and distended cells are long and narrow. To be able to function and produce adequate 
force, myocytes are organised into bundles. The cells within a bundle are connected via gap 
junctions to one another in series and in parallel, allowing the muscle bundle to act as a 
single unit, and so produced more force.  
In order for the uterus to function, the uterus needs to grow to accommodate the growing 
foetus. The myometrium does this by both hyperplasia, an increase in number and 
hypertrophy, an increase in the size of individual myocytes. At the beginning of gestation 
this is achieved primarily by hyperplasia, hypertrophy taking over towards the latter part of 
the first half of gestation, while growth in the second half of pregnancy is the result of 
stretch. 
At term, the myometrium needs to switch from a relatively inactive quiescent state, to one 
that is able to produce appropriate contractions. Too powerful contractions will cause foetal 
hypoxia and distress, while labour will be dysfunctional if contractions are too weak or 
uncoordinated. The myometrium achieves this by modulation of membrane potential and 
the propagation of action potential and Ca2+ signals throughout gestation. 
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1.2   Myometrial ion channels and transporters 
For schematic overview of myometrial ion channels and transporter see Figure 1.2. 
 
1.2.1   Ca2+ influx mechanisms 
1.2.1.1   Voltage operated Ca2+ channels 
Voltage operated Ca2+ channels (VOCC) are the principal mechanism of Ca2+ influx in 
spontaneously active myometrial tissue. The family of VOCC is comprised of six subtypes; L, 
N, P, Q, R and T types , of which L-type VOCC play a vital role in the generation of phasic 
contractility of the uterus, with the L-type VOCC blocker, nifedipine causing the abolishment 
of action potential, Ca2+ transient and the generation of force (Kuriyama et al. 1995; Shmigol 
et al. 1998b). T-type VOCC have also been suggested to be important to the uterus, 
although evidence of their physiological role in pregnant rat myometrium are contradictory 
(Amedee et al. 1987; Sperelakis et al. 1992; Young et al. 1993). 
L-type VOCC have a Ca2+ specific voltage sensitive inward current, with a threshold 
activation of around -40mV and are fully activated when the membrane is depolarised to 
more than -10mV (Jmari et al. 1986) and exhibit a slow voltage- dependent inactivation 
(Honore et al. 1989; Sperelakis et al. 1992). While L-type VOCC are controlled by voltage, 
they are also rapidly desensitised to sustained depolarisation, explaining the classic 
response to high-K+ depolarisation. Upon high-K+ stimulation there is an increase in [Ca2+]i, 
which rapidly falls to a lower maintained level, it is the smaller noninactivating current that 
is responsible for the maintained [Ca2+]i during sustained depolarisation, rather than the full 
initial current (Fleischmann et al. 1994). 
18 
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As L-type VOCC are voltage sensitive, they are modulated by all factors that influence 
membrane potential, allowing agonists to influence [Ca2+]i by altering the current through L-
type VOCC, which is primarily achieved through activation of Ca2+-activated K+ (KCa) or Cl
- 
(ClCa) channels (Arnaudeau et al. 1994; Zhou et al. 2007). In addition to being modulated by 
voltage, L-type VOCC are inactivated by increasing concentrations of Ca2+ and Mg2+ (Jmari et 
al. 1986; Sanborn 1995). Agonists may also modulate L-type VOCC in myometrial smooth 
muscle, with oxytocin a principal uterotonic suggested to work in part through modulation 
of L-type VOCC, although this remains controversial  (for review  see Sanborn et al. 1998). 
 
1.2.1.2     Non-selective cation channels / receptor-operated Ca2+ channels 
Unlike L-type VOCC, which have received lots of attention and whose mechanisms have 
generally been elucidated, there is still confusion regarding the existence, function and 
mechanism of non-selective cation channels (NSCC) and receptor-operated Ca2+ channels 
(ROC).  
In uterine smooth muscle, a non-selective cation channel has been suggested, being 
permeable to Ca2+, Na+ and K+ , and activated independently of agonist stimulation (Miyoshi 
et al. 2004). However, classification and properties of NSCC and ROC and currents generated 
by agonists or their downstream effectors in uterus is still controversial. In response to 
agonists binding to their receptors or activation by downstream effectors, both NSCC and 
ROC demonstrate poor Ca2+ selectivity and are often permeable to multiple ions (Benham 
1989; Kuriyama et al. 1995). These characteristic of NSCC and ROC result in confusion 
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regarding the differentiation between two, and so in this thesis will be considered as one 
entity. 
There are a number of lines of evidence to suggest that NSCC and ROC mediate a voltage- 
independent Ca2+ influx mechanism, and thus can be differentiated from VOCC (Murray et 
al. 1991). NSCC and ROC can also be distinguished from store operated Ca2+ channels (SOCC) 
as neither the depletion of the SR (Wang et al. 1991; Guibert et al. 1999) nor inhibition of IP3 
receptors by heparin prevent activation of NSCC or ROC by agonists (Albert et al. 2003c; 
Zholos et al. 2004). While NSCC and ROC constitute an independent Ca2+ influx pathway, due 
to their heterogeneous nature, there is currently no conformity regarding the mechanism of 
activation, current or channels involved in NSCC and ROC response in either spontaneous or 
agonist induced myometrial contractility.  
 
1.2.1.3     Store operated Ca2+ channels (SOCC) 
Store operated Ca2+ entry (SOCE), historically known as capacitative calcium entry (CCE), 
was identified over a quarter of a century ago, suggesting that a specific plasma membrane 
channel is activated upon agonist stimulated depletion of the SR, resulting in an influx of 
Ca2+ (Putney 2011). SOCE has been identified in many cell types; including both excitable 
and non-excitable cells. 
There are multiple lines of evidence to suggest the existence of SOCE in different cells 
including the uterus, based primarily on measurement of [Ca2+]i and force. Firstly by 
measuring [Ca2+]i, depletion of the store in the absence of external Ca
2+ substantially 
increases basal [Ca2+]i upon re-admission of Ca
2+ to the extracellular media; this increase in 
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basal [Ca2+]i is nifedipine resistant and can be induced by cyclopiazonic acid (CPA) and 
thapsigargin (SERCA pump inhibitors), excluding ROC / NSCC involvement. This evidence 
along with the use of non-selective inhibitors of SOCE, such as La3+ and SKF96365, have 
been taken to be highly suggestive of SOCE, and found in many smooth muscle types; 
colonic (Kovac et al. 2008), cultured A10 cells (Xuan et al. 1992), coronary arteries (Wagner-
Mann et al. 1992), gallbladder myocytes (Morales et al. 2004), pregnant and non-pregnant 
rat myometrium (Noble et al. 2009), and human myometrial cells (Shlykov et al. 2003). 
Electrophysiological evidence of SOCE has been primarily achieved by use of non-excitable 
tissue, as excitable cells have multiple ion channels, including L-type Ca2+ channels, with 
much greater conductance, and so it is difficult to isolate smaller currents, such as SOCE 
currents. Based primarily on evidence from non-excitable cells, a number of currents have 
been identified in response to Ca2+ depletion, describing a heterogeneous Ca2+ entry 
pathway. The first to be identified and that principally studied is ICRAC (Ca
2+ release activated 
Ca2+ current (Hoth et al. 1992). ICRAC is a non-voltage dependent, highly Ca
2+ selective (Hoth 
1995; Parekh et al. 2005) inwardly rectifying current (Hoth et al. 1992). With a low single 
channel conductance of around 0.02pS (Parekh et al. 2005) and has been identified in many 
cell types. 
Less is known about other currents induced by depletion of the store; Isoc (store operated 
currents) are relatively non-selective inwardly rectifying cation currents, often more 
permeable to Na+ than Ca2+, with generally higher single channel conductance than that of 
ICRAC,  around 3pS (Trepakova et al. 2000; Trepakova et al. 2001; Albert et al. 2003a). And 
have been identified in a number of smooth muscles; rabbit portal vein (Albert et al. 2002), 
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aortic myocytes (Trepakova et al. 2001), and pulmonary artery myocytes (Golovina et al. 
2001).   
The molecular basis for SOCE in uterine smooth muscle has yet to be identified, but theories 
are centred on a number of proteins thought to make up the channel or channels required 
for SOCE, as functional analysis suggests a  channel rather than an ion transporter is 
involved (Zweifach et al. 1993). The proteins thought to make these channels have been 
suggested to be; TRPC, Orai and STIM1.  
The functional relevance of SOCE in uterine smooth muscle, is still relatively unknown. 
Myometrium has a large reliance of L-type VOCC, so the need for SOCE may be minor under 
normal physiological conditions. The myometrial capability of SOCE is upregulated in 
pregnancy and labour (Tribe et al. 2000; Noble et al. 2009), and so has been suggested to be 
utilised by agonists during labour. Oxytocin, a principal regulator of myometrial contractility, 
has been shown in both human and rat to elicit a SOCE-like current and shows the sustained 
increase in [Ca2+]i, which is sensitive to La
3+ taken by many to be evidence of SOCE 
(Shimamura et al. 1994; Monga et al. 1999; Fu et al. 2000).  
 
 
1.2.2     Potassium channels 
There are a number of K+ channels found in the uterus, contributing to repolarisation of the 
action potential and setting the resting membrane potential. Modulation of K+ channels 
occurs through gestation and are thought to be responsible for control of uterine 
excitability, thus maintaining uterine quiescence during pregnancy. According to some 
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observations agonists can alter the function of K+ channels. Multiple K+ channels have been 
identified in the myometrium; Ca2+-sensitive K+ channel family, delayed rectifier, A-like and 
ATP-sensitive K+ channels. 
 
1.2.2.1     Ca2+-sensitive K+ channels 
There are a number of functional K+ channels found in uterine myocytes, although their 
complete role and mechanisms of function are still incompletely understood. Perhaps the 
most well studied of the K+ channels is the large conductance K+ channel (BKCa) also known 
as the maxi-K channel. BKCa are large conductance, voltage- and Ca
2+-sensitive K+ channels, 
which were first described in smooth muscle in 1986 (Benham et al. 1986). A number of 
splice variants have been indentified, differing in their sensitivities to Ca2+, voltage, 
hormonal sensitivity and ability to be phosphorylated (Brainard et al. 2007). They consist of 
four α-subunits that create a functional pore, with four modulatory β-subunits completing 
the protein. BKCa channels generally have a low affinity to Ca
2+ and thus due to their low 
Ca2+ sensitivity require high levels of Ca2+ around BKCa channels for their activation (Neher 
1998; Perez et al. 2001).  
BKCa channels alter the excitability of the uterus, and so are modulated throughout 
gestation, allowing the uterus to be in a quiescent state during gestation and in a more 
excitable state during labour. At the end of gestation BKCa isoforms with lower sensitivity to 
Ca2+ (Korovkina et al. 2001; Benkusky et al. 2002; Curley et al. 2004), and those more 
sensitive to phosphorylation increase (Zhu et al. 2005). Thus decreasing the functional role 
of BKCa channels at the end of gestation and during labour (Wang et al. 1998), allowing the 
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uterus to be in a more excitable state during labour. A number of endogenous and 
exogenous ligands are able to exert their effects through BKCa channels. BKCa channels 
mediate uterine relaxation in response to adenylyl cyclase (Okawa et al. 2000) and to nitric 
oxide (Okawa et al. 1999). Meanwhile relaxin, generated by the feto-placental membranes 
and ovaries during gestation increase the open probability state of BKCa channels (Meera et 
al. 1995). 
In addition to BKCa channels, two other Ca
2+ sensitive K+ channels have been identified in 
myometrial tissue; SK channel (small conductance Ca2+-sensitive voltage insensitive K+ 
channel (minK)) and IK channel (intermediate K+ channels), both like BKCa channels are 
involved in maintaining the resting membrane potential and the generation of a 
hyperpolarising current following the generation of an action potential (Noble et al. 2009; 
Noble et al. 2010). Three SK isoforms have been identified (SK1-3), produced by three genes 
(KCNN1-3) (Kohler et al. 1996). They are all voltage independent and activated by Ca2+ at 
around 1 μM, and have a small single channel conductance of between 4-14 pS (Wray et al. 
2010). There is evidence to suggest that Ca2+ release from the SR and Ca2+ entry from the 
extracellular space activate SK channels. Ca2+ binds to calmodulin, which is constitutively 
bound to the COOH terminus of the channel (Maylie et al. 2004) binding of Ca2+ leads to the 
opening of the channel.  
Functionally SK3 decreases influx of Ca2+ through VOCC (Brown et al. 2007) and 
overexpression of SK3 results in inefficient contractions for labour (Bond et al. 2000) 
suggesting that the membrane potential is in a hyperpolarised state, maintaining the block 
on labour. SK3 channels are also involved in relaxation induced by nitric oxide (Modzelewska 
et al. 2003a; Modzelewska et al. 2003b). 
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Whilst knowledge of SK channels is limited, information regarding IK channels is virtually 
non-existent. IK channels, formally SK4, have a 40 % αα homology to SK1-3 (Begenisich et al. 
2004). Have a conductance of 50-70 pS (Vandorpe et al. 1998), and unlike SK channels are 
insensitive to apamin and are not voltage dependent. 
 
1.2.2.2     Voltage-gated K+ channels  
Voltage-gated K+ channels (Kv channels) are essential for the control of spontaneous activity 
of myometrial smooth muscle (Aaronson et al. 2006). They are activated by depolarisation, 
are responsible for repolarisation of the membrane following the depolarisation phase of 
the action potential, and are also involved in maintaining resting membrane potential, 
contributing to the maintenance of uterine quiescent before labour (Lundgren et al. 1997). 
 
Kv channels constitute a heterogeneous family, giving numerous voltage-gated K+ currents, 
which differ in their kinetics and sensitivity to inhibitors (Brainard et al. 2007). In uterine 
smooth muscle, two types of Kv current have been identified; delayed rectifiers and rapidly 
inactivating currents (Wang et al. 1998; Knock et al. 1999; Knock et al. 2001). The principal 
voltage-gated K+ current identified in pregnant rat myometrium is a rapidly inactivating K+ 
current, generated by the Kv4 subfamily (Suzuki et al. 2005). Members of the Kv4 subfamily 
are known to be modulated by oestrogen and 17β-estradiol, increasing expression and 
current through these channels at parturition (Knock et al. 2001; Song et al. 2001). 
 
1.2.2.3     ATP-sensitive K+ channels 
The ATP-sensitive K+ channel (KATP), constitutes an inwardly rectifying K
+ channel, which has 
a role in the regulation of myometrial quiescent during pregnancy. They consist of Kir6 
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subunit forming the K+ channel, while the sulfonylurea receptor (SUR) confers ATP and other 
pharmacological sensitivities (Inagaki et al. 1996; Clement et al. 1997; Babenko et al. 1999). 
ATP inhibits the channel while MgADP stimulates, thus coupling cellular excitability to the 
metabolic state of the cell (Dunne et al. 1986), and so may provide the mechanistic link in 
dystocia, which has links to hypoxia (Heaton et al. 1993). 
Similar to other K+ channels, studies have suggested that the predominant isoform 
Kir6.1/SUR2B is downregulated towards parturition (Curley et al. 2002). KATP channels 
mediate relaxation in response to adenylyl cyclase and guanylyl cyclase (Okawa et al. 2000). 
 
 
1.2.3     Ca2+ activated Cl- channels 
Ca2+-activated Cl- (ClCa) channels have been found in the uterus (Coleman et al. 1987), with 
IClCa found in 30% of pregnant rat myocytes (Jones et al. 2004). They constitute a Cl
- efflux 
pathway, activated by Ca2+entering the cell via L-type Ca2+ VOCC or release from the SR 
(Jones et al. 2004), resulting in the generation of an inward current, and depolarisation of 
the cell membrane. ClCa channels are responsible for transient inward currents in smooth 
muscles (Wray et al. 2010), although there is currently no evidence for either Ca2+ sparks or 
STICs in the myometrium. But they do play a role in spontaneous phasic contractility; with 
inhibition reducing frequency and duration of contractions (Jones et al. 2004; Young et al. 
2009). They also play an important role in response to agonists, being activated by the 
increase in Ca2+, released from the SR in response to IP3 (Arnaudeau et al. 1994).  
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1.2.4     Ca2+ removal mechanisms 
Myometrial contraction is Ca2+-calmodulin dependent, and as such relaxation is dependent 
on a fall in [Ca2+]i. In resting cells there is a 10,000-fold concentration gradient across the 
plasma membrane, in order to maintain this steep concentration gradient and control the 
reduction in [Ca2+]i following influx through L-type VOCC, three Ca
2+ removal mechanisms 
exist; two Ca2+ extrusion systems which include the plasma membrane Ca2+-ATPase (PMCA) 
and the Na+/Ca2+ exchanger (NCX) and two systems of intracellular Ca2+ sequestration which 
include the SERCA pump of the sarcoplasmic reticulum (SR) and the Ca2+ uniporter of the 
mitochondria. Functionally PMCA along with NCX is critical in the efflux of Ca2+, with the 
PMCA being responsible for the extrusion of around 70% of total Ca2+ efflux (Shmigol et al. 
1998a). There is also a correlation with an increase in PMCA expression and the onset of 
labour (Tribe et al. 2000). 
 
1.2.4.1     PMCA 
The PMCA is a member of the P-type ATPase family, as such the pump uses hydrolysis of 
ATP to overcome the concentration gradient of Ca2+,  counter-transporting Ca2+ against H+, 
at a stoichiometery of one Ca2+ to one molecule of ATP hydrolysed (Wuytack et al. 1992). It 
is encoded by four genes, and alternative splicing gives rise to twenty-six isoforms, primarily 
with different regulatory properties (Carafoli 2004). Isoforms are composed of ten 
transmembrane spanning domains, primarily responsible for the catalytic domain and a long 
C- terminus regulatory domain (Monteith et al. 1995), and are localised within caveolae 
(Fujimoto 1993). 
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In its inactive state, PMCA is autoinhibited by its calmodulin binding domain within the 
regulatory domain, in a similar fashion to that found for myosin light chain kinase (MLCK), 
having a low affinity for Ca2+ (Verma et al. 1994). Upon binding calmodulin, auto-inhibition is 
removed, increasing both Ca2+ affinity and maximum velocity of the pump activity 
(Roufogalis et al. 1980; Muallem et al. 1981).The PMCA can also be activated by acidic 
phospholipids such as PIP2, protein kinases most commonly PKA and PKC, with the degree of 
activation and modulatory mechanism dependent on isoform expression (Monteith et al. 
1995; Penniston et al. 1998). Critically both G-proteins and agonists have been shown to 
activate and modulate PMCA, allowing another mechanism in which they can increase 
myometrial activity (Monteith et al. 1995).   
 
1.2.4.2   Na+/Ca2+ exchanger  
The Na+/Ca2+ (NCX) exchanger is an electrogenic antiporter, using the Na+ gradient 
maintained by the Na+, K+-ATPase to drive the extrusion of one Ca2+ for three Na+. In 
physiological condition the NCX will act to extrude Ca2+, but can reverse depending on the 
prevailing concentrations of intra- and extracellular Na+ and membrane potential (Aickin et 
al. 1984; Carafoli 2004). Compared to the PMCA, NXC has a lower affinity for Ca2+ but a 
higher capacity system, so it is suggested that NCX has a role at higher [Ca2+]i, rather than 
fine tuning responses which is more suited to the PMCA (Matthew et al. 2004). While the 
PMCA has been shown to be responsible for around 70% of Ca2+ efflux, the NCX is 
responsible for the remaining 30% (Shmigol et al. 1998a). As with many proteins, there is a 
gestational change in the reliance of the NCX, having a greater role in Ca2+ extrusion in 
response to agonists in late pregnancy (Taggart et al. 1997). 
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Three genes (NCX 1-3) and alternative splicing are responsible for the eight NCX family 
members, giving a 938 amino acid protein containing nine transmembrane domains, with a 
large cytosolic loop between transmembrane domains 5-6 thought to contain the regulatory 
domains; including biding sites for calmodulin (Carafoli 2004). Similarly to PMCA, they are 
also localised to caveolae in smooth muscle (Moore et al. 1993; Juhaszova et al. 1994). 
 
1.2.4.3   Na+/ K+-ATPase 
Normal functioning of myometrial smooth muscle is dependent on maintenance of the 
correct ionic balance across the membrane. High intracellular K+ and low Na+ concentrations 
require the active transport of both ions across the membrane, which is achieved by the 
Na+, K+-ATPase. The Na+, K+-ATPase, like the PMCA and SERCA is a member of the P-type 
ATPase, and so hydrolysis of ATP provides the energy to counter transport two K+ and three 
Na+ against their concentration gradients (Floyd et al. 2007).  
Na+, K+-ATPase is composed of three subunits; α subunit responsible for catalysis and 
transport of ions, β subunit which modulates the α subunit, and μ subunit which is also 
involved in modulation of Na+, K+-ATPase activity.(Floyd et al. 2007; Floyd et al. 2010). There 
are multiple isoforms of each subunit, expression been both species and tissue specific, 
these isoforms have different sensitivities and regulation by [Na+]i, [Ca
2+]i , PKA and PKC 
(Decollogne et al. 1993). In uterine smooth muscle, there is a switch in isoform expression in 
pregnancy, although the functional significance of this is unknown (Floyd et al. 2010). 
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1.3     The sarcoplasmic reticulum 
Experiments in Ca2+ free solutions, showing that contractile responses continued in the 
absence of external Ca2+, first identified a role for a smooth muscle intracellular Ca2+ store 
(Hurwitz et al. 1967). The sarcoplasmic reticulum (SR) was first suggested to be the 
intracellular Ca2+ store in smooth muscles in 1971 based on EM studies (Gabella 1972) and 
the ability of Sr3+ to accumulate in the SR (Somlyo et al. 1971). Since then it has been 
established that the SR plays a pivotal role in agonist induced contractility in myometrial 
smooth muscle (Shmygol et al. 2005). 
 
 
1.3.1    Ca2+ release 
 
1.3.1.1     Inositol 1,4,5-triphosphate receptors 
Inositol 1,4,5-triphosphate receptors (IP3R) are one of two SR Ca
2+ release pathways, found 
in smooth muscle. Due to the non-functional ryanodine receptors (RyR), it is the primary 
release mechanism found in uterine smooth muscle. They release Ca2+ from the SR in 
response to agonist stimulation. Binding of G-protein coupled receptors (GPCR), activates 
phospholipase C (PLC), leading to the hydrolysis of phosphatidylinositol 4,5-biphosphate 
(PIP2) yielding diacylglycerol (DAG) and inositol 1,4,5-tripphosphate (IP3) (Berridge et al. 
1984). IP3 directly activates IP3R via the N-terminal ligand binding domain allowing the efflux 
of Ca2+ (Yoshikawa et al. 1996). 
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IP3R exist as tetrameric structures, having a monomeric molecular mass of around 300 KDa 
and can consist of both homo- and heteromeric assemblies (Devogelaere et al. 2008). Three 
distinct IP3R gene products (1-3) have been identified, all three are structurally and 
functionally similar (Mikoshiba et al. 1994), although expression subtype has not to date 
been determined for the myometrium. 
In addition to being activated by IP3, there are a number of intracellular modulatory 
mechanisms, the principal being [Ca2+]i. [Ca
2+]i has a biphasic action on the effects of Ca
2+ 
release by IP3R; at low concentrations IP3R are stimulated and so require less IP3 to give a 
bigger Ca2+ release, while at higher [Ca2+]i IP3R are suppressed, needing more IP3 to give the 
same Ca2+ release (Patel et al. 1999; Wray et al. 2010).  
 
1.3.1.2     Ryanodine receptors 
RyR are the other Ca2+ release mechanisms found in smooth muscle, named after the plant 
alkaloid which it binds. RyR are homotetramers forming a central pore, allowing the co-
ordinated movement of Ca2+ through the pore, with each subunit associated with a 
regulatory binding protein FKBP (Meissner 2004). They have a large cytosolic domain, 
containing binding sites for Ca2+, calmodulin in addition to phosphorylation sites (Wray et al. 
2010), allowing for the modulation of Ca2+ flux. The principal endogenous activator is Ca2+, 
and similar to IP3R, Ca
2+ has a biphasic response, activating RyR at low concentrations, whilst 
inactivating at higher cytosolic concentrations (Meissner 1994). 
There are three isoforms of RyR (1-3), encoded by distinct genes, having variable 
pharmacological and kinetic profiles (Sutko et al. 1997). All three isoforms can be expressed 
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in smooth muscle, including rat myometrium, with RyR3 being the dominant isoform 
(Martin et al. 1999). Although RyR are expressed in rat myometrium, Ca2+ sparks have not 
been identified, and so RyR are considered to be non-functional (Burdyga et al. 2007). 
 
1.3.1.3     Ca2+ leak 
There is a low level constitutive non-regulated Ca2+ leak through the SR membrane; shown 
by inhibiting Ca2+ channels and preventing Ca2+ reuptake to the store by SERCA. The nature 
of this Ca2+ leak is not understood, but has been suggested to be needed to balance SERCA 
activity (Camello et al. 2002). In uterine smooth muscle, little investigation of Ca2+ leak has 
taken place, although in human uterus little depletion occurred with inhibition of SERCA 
(Young et al. 1999). 
 
 
1.3.2     Ca2+ uptake 
 
1.3.2.1     Sarco/endoplasmic reticulum Ca2+-ATPase 
The sarco / endoplasmic reticulum Ca2+-ATPase  (SERCA) is a P-type ATPase responsible for 
the uptake of Ca2+ into the SR. Similar to the PMCA and Na+,K+-ATPase, it utilises the energy 
from ATP hydrolysis, to transport two Ca2+ into the SR for every ATP hydrolysed, and so acts 
to maintain the store. 
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The pump was first purified in 1970 (MacLennan 1970), with the mechanism of action 
elucidated in 2002 (Toyoshima et al. 2002). Two Ca2+ from the cytosolic side bind, and upon 
phosphorylation of Asp351 by ATP, Ca2+ is translocated across the membrane by the high 
energy intermediary and so becomes a low energy intermediary releasing Ca2+ into the SR 
lumen (for review see Wray et al. 2010). During this cycle two or three protons are counter 
transported ensuring partial charge balance (Levy et al. 1990). 
There are 3 mammalian isoforms, encoded by three genes (ATP2A1, ATP2A2, ATP2A3), 
known as SERCA-1, -2, and -3. In addition, alternative splicing occurs, giving rise to SERCA1- 
a and –b, and SERCA2 – a and -b. SERCA2 is found in smooth muscles, with a greater 
expression of SERCA2b in the uterus (Khan et al. 1993), while both are expressed to a 
greater extent in pregnant compared to non-pregnant and in labouring samples (Khan et al. 
1993; Tribe et al. 2000). All isoforms are structurally similar, and are composed of three 
parts; a large cytosolic head, constituting half of SERCA, a stalk domain and a 10 
transmembrane spanning domain (Wray et al. 2010).   
The principal regulator of SERCA is phospholamban, when bound it inhibits SERCA by lowing 
its apparent affinity for Ca2+ through direct protein-protein interactions (Asahi et al. 2003), 
but is phosphorylated by both PKA and Ca2+-calmodulin-dependent protein kinase II, 
resulting in reduction in SERCA inhibition (Simmerman et al. 1998). SERCA activity is also 
modulated by a number of other regulators including insulin-receptor substrate (IRS1/2), 
Ca2+ binding protein S100A1 and Bcl-2 (Wray et al. 2010). It is also regulated indirectly by 
Ca2+ through the protein calreticulin, when luminal [Ca2+]i are low calreticulin does not bind 
to SERCA, removing inhibition, therefore increasing SERCA activity, increasing the ability to 
fill the store (Michalak et al. 1999). 
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1.4     Excitation – contraction coupling 
The uterus is a myogenic organ, that is, contractions can be initiated intrinsically by the 
myocyte, without the involvement of an external stimulus, such as nervous or hormonal 
inputs. In uterine smooth muscle, contraction is Ca2+-dependent, with an increase in [Ca2+]i 
needed for contraction to occur, this increase in [Ca2+]i is the result of Ca
2+ influx through L-
type VOCC as part of the action potential, or by other mechanism such as store operated 
Ca2+ entry and receptor operated Ca2+ entry. In smooth muscle excitation-contraction 
coupling can occur through two mechanisms; firstly by electro-mechanical coupling, a term 
coined to describe the relationship between membrane potential and the induction of 
mechanical force, explaining the relationship between action potential and force production 
(Somlyo et al. 1994). The second mechanism is by pharmaco-mechanical coupling, whereby 
stimuli result in an increase in the production of force that is not dependent on changes in 
membrane potential, although changes in membrane potential may occur, examples of this 
are Ca2+ entry through ROC, SOCE and Ca2+ sensitisation (Somlyo et al. 1994). 
 
1.4.1    Electro-mechanical coupling 
As previously described, electro-mechanical coupling is the relationship between membrane 
potential and the mechanical output of a muscle. This relationship is pivotal to uterine 
smooth muscle contraction, both spontaneous and agonist induced contractility is 
dependent upon depolarisation of the membrane resulting activation of an action potential, 
with a resulting influx of Ca2+through L-type VOCC. Changes in membrane potential by 
agonists and other modulators of uterine contractility, will alter the frequency of action 
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potentials and therefore force characteristics. They are able to do this by working on ion 
channels, such as BKCa and ClCa, as previously discussed. 
 
1.4.1.1     The action potential 
In smooth muscle there are two forms of action potential; spike-like and plateau. Rat 
longitudinal myometrial tissue, unlike other types of smooth muscle, exhibit spike-like 
action potentials and do not possess plateau-like action potentials found in other species, 
and so only spike-like action potentials found in rat myometrial tissue will be discussed 
(Mironneau 1973; Kuriyama et al. 1976; Parkington et al. 1988). 
Unlike other smooth muscle, the mechanism behind the initiation of action potentials in 
uterine smooth muscle have yet to be identified. In other smooth muscle, pacemaker cells 
have been identified, they have an unstable fluctuating membrane potential. When this 
membrane potential reaches threshold activation of VOCC, an action potential is initiated. 
Whilst pacemaker cells have not been identified in the uterus, slow rhythmic alterations in 
membrane potential have been detected, although the underlying ionic mechanism has yet 
to be elucidated (Casteels et al. 1965; Sanborn 1995). 
Once the slow wave of depolarisation reaches the threshold activation of L-type VOCC, 
around -40mV (Jmari et al. 1986) channels open and there is an influx of Ca2+, this in 
conjunction with an increase in Na+ permeability results in the upstroke of the action 
potential (Shmigol et al. 1998b). The repolarisation phase, downstroke of the action 
potential is due to a decrease in the inward Ca2+ and Na+ currents and the development of 
an outward current (Mironneau et al. 1980; Mironneau et al. 1981). L-type VOCC as 
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discussed previously, are voltage sensitive, and upon depolarisation are inactivated (Honore 
et al. 1989; Sperelakis et al. 1992), this in addition to time- and Ca2+- dependent inactivation 
of L-type VOCC will drastically reduce Ca2+ influx, whilst voltage and Ca2+-dependent K+ 
channels are activated resulting in the repolarisation of the cell (Mironneau et al. 1980; 
Mironneau et al. 1981). 
 
 
1.4.1.2     Relationship between action potentials, Ca2+ spikes and force 
Unlike other forms of smooth muscle, rat myometrial tissue only exhibit spike like action 
potentials, with force characteristics dependent upon the characteristics of the bursts of 
action potentials. Each action potential correlates to an individual Ca2+ spike, and a transient 
increase in force (Burdyga et al. 2009). The higher the frequency of action potentials with a 
burst of action potentials, increases the frequency of concurrent Ca2+ spikes, resulting in a 
higher production of force, as the result of summation (Mironneau 1973; Burdyga et al. 
2009) (Figure 1.4.1.2). 
In addition to action potentials being responsible for the amount of force produced, they 
are also responsible for the frequency and duration of contractions. Myometrial 
contractions are Ca2+-dependent, and as such are activated by influx through L-type VOCC as 
part of the action potential, and so contraction frequency is dependent upon the frequency 
of the bursts of action potentials. While duration will remain for the length of the action 
potential burst (Mironneau 1973), with rate of relaxation also dependent upon the rate of 
MLC dephosphorylation. 
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1.4.1.3     Propagation of action potentials 
In order for the uterus to function, it needs to provide phasic contractions of the 
appropriate duration, frequency and force. To do this, action potentials must be 
appropriately propagated throughout the tissue, allowing synchronisation of the 
longitudinal muscle bundles. The ability of myometrial tissue to initiate and propagate 
action potentials, is constantly changing. The initiation site can move, while the speed, 
direction and length of propagation can alter within minutes (Lammers et al. 1994; Lammers 
et al. 1998).  It is limitations in the spatial spread of action potentials that maintain uterine 
quiescence during gestation, with an increase in the propagation, velocity and conduction of 
action potentials increasing towards parturition, giving the synchronous activity needed to 
expel the foetus (Cole et al. 1985; Lammers et al. 1994; Doring et al. 2006). 
Intracellular communication is thought to be provided by gap junctions. Gap junctions are 
specialised conduits that allow direct intracellular communication by the passage of 
molecules of up to 1000 Da, directly coupling both electrical and metabolic states of 
individual cells. They are modulated throughout gestation, with increasing density at the 
end of gestation, correlating with the increase in electrical coupling (Cole et al. 1985; 
Lammers et al. 1994); while gap junction density is minimal during gestation, explaining the 
lack of propagation and conduction of action potentials during pregnancy. The importance 
of gap junctions in contractility is highlighted by inhibition of gap junctions, which results in 
delayed parturition (Cole et al. 1985; Lammers et al. 1994; Doring et al. 2006). 
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1.4.2     Pharmaco-mechanical coupling 
Pharmaco-mechanical coupling refers to the production of force, which is independent of 
changes in the membrane potential, often induced by endogenous and exogenous agonist. 
In uterine smooth muscle, this can occur through a number of mechanisms, such as; Ca2+ 
entry through ROC/NSCC, SOCC and release from the SR, it may also result from Ca2+-
sensitisation. Whilst pharmaco-mechanical coupling is not initiated by a change in 
membrane potential, it is important to note that some pharmaco-mechanical coupling 
mechanisms may have downstream effects on membrane potential, and dependent 
processes.  
 
1.4.2.1     Ca2+ entry   
The binding of an agonist to its receptor can result in the influx of both Ca2+ and other ions 
into the cell, increasing [Ca2+]i, resulting in contractility. They are able to do this by two 
mechanism; receptor-operated Ca2+ entry (ROCE) of store-operated Ca2+ entry (SOCE). ROCE 
is dependent upon the activation of a heterogeneous pool of either Ca2+ or non-specific 
channels as a result of agonist binding, or its downstream effects (as previously discussed). 
While SOCE, is activated in response to agonist depletion of the SR, and similar to ROCE, has 
been identified as involving both Ca2+ and non-selective currents (as previously discussed). 
In addition to increasing [Ca2+]i, changes in the conductance of either Ca
2+ or other ions as a 
result of either ROCE or SOCE will effect membrane potential and thus modulate L-type 
VOCC, contributing to the response of agonists. (Refer to ROC or SOCE for detailed 
discussion) 
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1.4.2.2     SR Ca2+ release 
In addition to the activation of ROCE, agonists often release Ca2+ from the SR. Binding of G-
protein coupled receptor (GPCR) results in the activation of PLC, increasing IP3, IP3 binds to 
IP3R on the SR, releasing Ca
2+, increasing [Ca2+]i (See IP3R for more detail). The release of 
Ca2+ from the SR, often results in depletion of the store, and activation of SOCE, further 
enhancing [Ca2+]i. 
 
1.4.2.3    Ca2+ sensitivity 
Agonists are able to modulate the Ca2+ sensitivity of the contractile machinery, and so 
smooth muscles are able to produce more force, for the same [Ca2+]i. There is evidence of a 
number of uterotonics working through Ca2+ sensitisation; including oxytocin (Izumi et al. 
1996). Although evidence of Ca2+ sensitisation in the myometrium is limited, evidence of its 
functional importance and its mechanisms are more prevalent in other smooth muscles, 
with Ca2+ sensitisation especially important to the creation of tone in vascular smooth 
muscle (Pfitzer 2001). The primary mechanisms by which modulation of Ca2+ sensitisation 
occurs is by Ca2+-independent modulation of myosin light chain kinase (MLCK) and or 
myosin light chain phosphotase (MLCP), primarily through PKC and rho-kinase, thus altering 
the proportion of MLC20-P for a given [Ca
2+]i. (See MLCK and MLCP for more detailed 
discussion). 
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1.5     Mechanism of contraction 
1.5.1     Basis of muscle contraction 
Uterine smooth muscle contraction is Ca2+-calmodulin-myosin light chain kinase dependent, 
with multiple lines of evidence showing that removal of this pathway results in the 
abolishment of contractility (Longbottom et al. 2000). During stimulation, whether that be 
spontaneous or agonists induced, [Ca2+]i rise from around 10
-7 to 10-5.  Ca2+ binds to and 
activates calmodulin. Ca2+-calmodulin has two pivotal functions in smooth muscle 
contractility; firstly it activates myosin light chain kinase (MLCK), the enzyme responsible for 
the phosphorylation of MLC20. Phosphorylated-MLC20  (MLC20-P) activates the myosin 
ATPase, allowing myosin to interact with actin as part cross-bridge cycling and so force is 
generated (Figure 1.5.1) (Word 1995) (Figure 1.5.1). The second function of Ca2+-calmodulin 
is its interaction with caldesmon, upon binding caldesmon inhibition of actin-myosin 
interactions is abolished, and force can be produced (Wang 2001). 
Upon phosphorylation of MLC20 and removal of caldesmon block, actin thin filaments and 
myosin are able to interact in cross-bridge cycling and the generation of force. This is the 
same biochemical mechanism that occurs in striated muscle. Briefly by hydrolysis of ATP, 
the myosin head undergoes a conformational change, pulling the actin thin filaments, 
resulting in contraction. The cycle occurs in four steps; firstly myosin lacking nucleotide 
binding is tightly bound to actin, upon ATP binding to myosin, there is a decrease in affinity 
for actin, and thin and thick filaments are no longer attached. Hydrolysis of ATP results in a 
conformational change that causes the myosin head to become primed. Weak interactions 
between actin and myosin result in the release of ADP and inorganic phosphate (Pi), 
increasing the interaction and triggering the power-stroke, were the myosin head regains its 
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original shape, pulling the thin filaments along the myosin, which returns the actin and 
myosin to the beginning of the cycle.  
Relaxation of smooth muscle occurs when [Ca2+]i is restored to resting levels, as a result of 
efflux from the cell by PMCA and NCX or the sequestering of Ca2+ into the SR by SERCA 
(Matthew et al. 2004). The decrease in [Ca2+]i results in a reduction in Ca
2+-calmodulin, 
which can therefore no longer activate MLCK, while dephosphorylation of MLC20 still occurs 
via MLCP. This shift in the balance between phosphorylation and dephosphorylation of 
MLC20 results in the relaxation of the muscle. 
While this pathway is essential to contraction, modulation of many steps occurs in the fine 
tuning of muscle contractions. This primarily occurs through MLCP, MLCK and the thin 
filaments.  
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1.5.2    Contractile proteins 
Uterine, similar to other smooth muscles, are composed of two major contractile proteins; 
thick and thin filaments, with thin filaments composed of actin and tropomyosin along with 
the regulatory proteins caldesmon and calponin (Hodgkinson 2000). Smooth muscle 
generate force with cross-bridge cycling as found in striated muscle, and contains generally 
the same contractile apparatus, with a few obvious exceptions; troponin is not expressed in 
smooth muscle, and the addition of the regulatory protein caldesmon, calponin and 
calmodulin. The structural organisation is very different, while striated muscles are 
composed of highly structured sarcomeres, smooth muscle is less organised, and 
maintained by dense bodies (Ashton et al. 1975; Ali et al. 2005)(See figure 1.5.2 for 
schematic diagram of contractile proteins and organisation). 
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1.5.2.1     Myosin (thick filaments) 
Myosin comprises a large family of ATPases, who in conjunction with actin are responsible 
for the movement during cross-bridge cycling. Myosin II is responsible for the contraction of 
muscle, and there are multiple homologues, having the same basic structure; hexamers 
composed of two myosin heavy chains (230KDa) and two pairs of myosin light chains (MLC) 
(17 and 20KDa). The two heavy chains form an α-helical coiled-coiled structure that includes 
the sites of myosin molecule association for filament formation, and extends through the 
hinge region (converter domain), responsible for the movement of the globular head, into 
the globular head, which is the site of actin binding and ATP hydrolysis (Eddinger et al. 
2007). The MLCs are associated with the globular head region of the heavy chain, were 
MLC20 is thought to inhibit the actin-activated ATPase, upon phosphorylation, at either 
Ser19 or Thr18, there is a conformational change and this inhibition is removed (Ikebe et al. 
1983; Ikebe et al. 1988). 
 
1.5.2.2     Thin filaments  
While myosin phosphorylation is the determining factor in smooth muscle contractility, it is 
the smooth muscle thin filaments that are thought to provide the fine tuning regulation 
required for effective contractility. Smooth muscle thin filaments are composed of actin, 
tropomyosin, caldesmon and calmodulin in ratios of 14:2:1:1. All four components are 
needed for correct cross-bridge cycling and its regulation. 
The principal component of thin filaments is actin. In smooth muscle, actin is made up of 
smooth muscle α-actin (ACTA2 gene) and γ-actin (ACTAG2 gene), with proportions 
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dependent upon the smooth muscle (Marston et al. 2008). Actin is a highly conserved 
protein with a molecular mass of 42 KDa. With all actin monomers (globular G-actin) able to 
polymerise and form fibrillar F-actin macromolecules, forming a right handed helix 
composed of two strands that cross every 36 nm, containing 13 G-actin (Hodgkinson et al. 
1997a; Hodgkinson et al. 1997b; Hodgkinson 2000). Each G-actin has a high-affinity myosin 
head binding site. 
Tropomyosin is the second most abundant thin filament protein. There are two smooth 
muscle isoforms α- and β- tropomyocin, produced by alternative splicing. They are 
approximately 284 amino acids in length, existing as heterodimers in a predominantly α-
helical coiled-coiled structure, wrapped around the α-helical actin strands (Jancso et al. 
1991; Hodgkinson 2000).  
Caldesmon is the third most abundant thin filament protein, after actin and tropomyocin. It 
is an elongated molecule of approximately 87 KDa, composed of three domains. The C-
terminal region is considered to be the most important domain with primary binding sites 
for; actin, calmodulin and other phosphorylation sites (Wang 2001). While the N-terminal is 
also able to interact with actin and calmodulin, it can only do this weakly, it also contains a 
myosin binding domain (Wang 2001). The two regions are interspaced by a middle spanning 
region, composed of a highly charge repeating sequence with no clear function. It is this 
spanning region that gives the shape to caldesmon, appearing as a stretch dumbbell (Wang 
2001). 
Caldesmon acts to inhibit myosin ATPase activity (Ngai et al. 1984) acting as a break to 
myometrial contractility. In conjunction with its role as an inhibitor to myometrial 
contractility, expression is significantly increased in pregnancy (Word et al. 1993).It is 
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thought to act as a myometrial contractile inhibitor by tethering actin and myosin together 
and blocking their direct interaction. The N-terminal region of caldesmon binds myosin, 
while its C-terminal binds actin, in a low [Ca2+]i /unstipulated state this configuration blocks 
the binding of unphosphorylated myosin heads to actin. Upon stimulation, Ca2+-calmodulin 
interacts with caldesmon resulting in the movement of caldesmon away from actin/myosin 
interaction sites (Wang 2001). In addition to Ca2+-calmodulin inhibition of caldesmon, it is 
also able to be phosphorylated in a non-Ca2+ dependent manner by PKC and protein kinase 
II (Gorenne et al. 2004). 
Calponin is another regulatory protein associated with the thin filaments, and found in all 
smooth muscles. It is a monomeric protein of 34 KDa (Winder et al. 1993), with similar 
binding characteristic to caldesmon, able to interact with actin (Childs et al. 1992) myosin 
(Szymanski et al. 1997) and Ca2+-calmodulin (Winder et al. 1993). Unlike caldesmon, it 
appears that the only physiological relevant interaction partner is actin (Winder et al. 1993). 
Calponin inhibits the myosin ATPase activity rather than reducing Ca2+-dependent myosin 
phosphorylation (Winder et al. 1990) and is thought to involve inhibition of a catalytic step 
ATPase cycle, most probably the rate limiting step of ADP or inorganic phosphate (Pi) 
release.    
Calponin itself is regulated by phosphorylation, resulting in the abolishment of calponin 
inhibition on the actin-activated ATPase (Winder et al. 1993). Both PKC and calmodulin 
kinase II have been shown to phosphorylate calponin (Winder et al. 1990) while 
dephosphorylated by a type 2A protein serine/threonine phosphatase (Winder et al. 1992). 
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1.5.3    Regulatory protein  
 
1.5.3.1    Myosin light chain kinase 
Myosin light chain kinase (MLCK ) is a specific serine/threonine protein kinase, capable of 
phosphorylating only MLC20, at either Ser19 or Thr18, activating cross-bridge cycling and 
thus the production of force (Moore et al. 2001; Takashima 2009). It is a monomer, 
consisting of; a catalytic domain, calmodulin regulatory domain, an actin-binding domain at 
its N-terminus and a myosin binding region at its C-terminal (Guerriero et al. 1986; Kohama 
et al. 1996; Stull et al. 1998; Kudryashov et al. 1999).  
 
The catalytic domain is responsible for the phosphoylation of MLC20 at Ser19, at higher 
concentration MLCK will also phosphorylate Thr18 (Ikebe et al. 1986; Horowitz et al. 1996). 
At low [Ca2+]i the autoinhibitory calmodulin regulatory domain intrasterically inhibits MLCK 
activity (Gallagher et al. 1993; Moore et al. 2001). Upon influx of Ca2+, 3-4 Ca2+ bind to 
calmodulin, Ca2+-calmodulin binds to the calmodulin binding domain of MLCK, resulting in a 
conformational shift and the removal of the autoinhibition of the catalytic subunit by the 
calmodulin binding domain, allowing the phosphorylation of MLC20  (Olson et al. 1990; 
Moore et al. 2001). 
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1.5.3.1.1    Modulation of MLCK 
MLCK is the protein responsible for activation of MLC20, and as such its activity is tightly 
regulated. To date less is known about the regulation of MLCK compared to the more 
interesting MLCP regulation, but it is known that regulation, similar to MLCP, is primarily 
dependent upon phosphorylation, resulting in a decrease in activity. MLCK can be 
phosphorylated by a number of modulators; primarily Ca2+-calmodulin-activated protein 
kinase II, but also protein kinase A (PKA) and protein kinase C (PKC) (Moore et al. 2001). 
Phosphorylation of MLCK results in a reduction in affinity of MLCK for the Ca2+-calmodulin 
complex, therefore reducing the amount of activated MLCK (Stull et al. 1998; Pfitzer 2001). 
 
1.5.3.2     MLCP 
Myosin light chain phosphatase is the only known endogenous phosphatase capable of 
dephosphorylating MLC20, it therefore has a pivotal role in the regulation of myometrial 
contractility. MLCP is composed of three subunits; a 110- to 130 KDa regulatory subunit 
(MYPT1), a 37 KDa catalytic subunit (PP1c) and a 20 KDa subunit of unknown function 
(Hartshorne 1998). 
For maximal functioning of the catalytic subunit, it needs to be bound to MYPT1. This is 
achieved though the PP1c binding domain located at the N-terminal of MYPT1 in addition to 
the ankyrin repeats (Alessi et al. 1992; Shirazi et al. 1994). The ankyrin repeats are a 
dominant feature of the N-terminal of the protein, as they are found in a variety of proteins, 
they are thought to confer many of the biding properties of MLCP acting as an appropriate 
platform for interactions (Hartshorne 1998). It is also likely that the ankyrin repeats are 
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required for binding P-MLC20  (Hirano et al. 1997), in addition to binding myosin and PP1c, 
MYPT1 also contains the phosphorylation sites for rho-kinase inhibition (Hartshorne 1998). 
While the regulatory subunit is needed for regulation and maximal function of the 
holoenzyme, it is the catalytic, PP1C subunit that is responsible for the dephosphorylation of 
P-MLC20, while the function of the 20 KDa subunit has not been resolved (Hartshorne 1998). 
 
1.5.3.2.1     Modulation of MLCP 
As the phosphatase responsible for dephosphorylation of MLC20, it is the principal target for 
mechanisms involving Ca2+ sensitisation, which is achieved though inhibition of MLCP. 
Inhibition of MLCP, occurs primarily through three mechanisms; firstly phosphorylation of 
Thr696 within the regulatory (MYPT1) subunit of MLCP has been shown to inhibit MLCP 
activity (Ichikawa et al. 1996; Kimura et al. 1996; Feng et al. 1999). This occurs primarily 
through rho-kinase (Kimura et al. 1996) activated as part of the G-protein signal 
transduction pathway, via Rho-guanine nucleotide exchange factors (Somlyo et al. 2000). 
Binding of GPCR also results in the second mechanism of Ca2+ sensitisation through MLCP. 
Activation of PLC results in the generation of DAG from the hydrolysis of PIP2, DAG can 
activate PKC, which phosphorylates and activates CPI-17, a potent inhibitor of the catalytic 
subunit of MLCP (Eto et al. 1995; Senba et al. 1999). Arachidonic acid also plays an 
important role in the mechanisms of Ca2+ sensitisation, it mediates the dissociation of the 
holoenzyme and therefore inactivation of MLCP, resulting in a seven fold reduction in 
myosin-targeted phosphatase activity (Gong et al. 1992). In addition to this it is also able to 
activate rho-kinase (Fu et al. 1998; Araki et al. 2001) and atypical PKC (Gailly et al. 1997) 
therefore enhancing those Ca2+ sensitisation pathways. 
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1.5.3.3     Calmodulin 
Calmodulin is a ubiquitously expressed protein, involved in a variety of Ca2+-dependent 
cellular processes. It is 148 residues long (17 KDa), with a dumbbell shape, having two 
globular domains connected by a long central helix (Babu et al. 1985; Ikura et al. 1992). At 
low [Ca2+]i calmodulin exists in the cytosol and does not interact with target proteins, upon 
stimulation of the cell and influx of Ca2+ through L-type VOCC or release from the SR, Ca2+ is 
able to bind and activate calmodulin. Each of the two globular domains has two Ca2+ binding 
sites, and upon binding Ca2+, calmodulin undergoes a conformational change allowing it to 
modulate the activities and function of a number of enzymes and proteins, including; MLCK, 
caldesmon and PMCA as previously discussed (Word 1995). 
 
 
1.6     Prostaglandins 
Prostaglandins (PG) are a family of bioactive 20-carbon chain lipids derived from arachidonic 
acid, and are a subfamily of the eicosanoids. They are biological lipids, which act in an 
autocrine and paracrine fashion and are produced by all nucleated cells, except 
lymphocytes. There are five prostaglandins, involved in a wide range of biological functions; 
platelet aggregation, stomach acid secretion in addition to both contraction and relaxation 
of smooth muscle. There are five prostaglandins, named alphabetically in order of discovery; 
PGTXA2, PGD2, PGE2, PGI2 and PGF2α.   
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The two principal prostaglandins within the uterus are PGF2α and PGE2, where they play a 
major role in both the initiation and maintenance of labour and have also been suggested to 
be the cause of preterm labour.  
 
1.6.1     Prostaglandin F2α 
PGF2α is one of the five prostaglandins, and is the principal prostaglandin in the uterus, 
where it functions as a uterotonic. As such expression is tightly regulated by synthesis and 
degradation, while function is dependent on PGF2α expression, it is also dependent on the 
expression of its receptor (FP). Aberrant levels correlate with pre-term birth (Olson 2005) 
and endometriosis (Jabbour et al. 2004). 
 
1.6.1.1     Function  
PGF2α is a uterotonic, increasing the contractility of the myometrium. It has been proposed 
that PGF2α plays a role in parturition, there are several lines of evidence to suggest this; 1) 
PGF2α increases contractility, 2) concentrations increase towards parturition, 3) labour can 
be induced by PGF2α administration and 4) inhibition delays parturition.  
PGF2α is a myometrial stimulant. It is strong enough to initiate phasic contractility in 
quiescent tissue (Reiner et al. 1976), while it increases both the amplitude, duration and 
frequency of spontaneous contractility, in addition to an increase in basal tone (Reiner et al. 
1976; Crankshaw et al. 1992; Phillippe et al. 1997; Sharif 2008). Paradoxically there has been 
one study in which very low PGF2α concentration (10
-12) resulted in a reduction in basal tone, 
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without changing other force parameters (Khan et al. 2008), although no reasoning was 
given and no further studies have reproduced this effect.  
While PGF2α increases myometrial contractility, the uterus also display a change in sensitivity 
towards PGF2α; increasing towards parturition. The myometrium is most sensitive to PGF2α 
on day 10, after which time it falls until day 18 where sensitivity starts to increase, 
continuing until parturition (Reiner et al. 1976; Crankshaw et al. 1992). Whilst the uterus is 
more sensitive to PGF2α on day 10, the maximal tension is achieved at the end of gestation 
(Crankshaw et al. 1992). In addition to gestation affecting sensitivity and the degree of 
mechanical output, the anatomical area also affects the amount of force produced by PGF2α, 
with the ovarian portion of the myometrium of non-pregnant rats giving a greater 
mechanical output than the cervical section to the same concentration of PGF2α (Oropeza et 
al. 2002). While longitudinal myometrial strips are more sensitive to PGF2α than circular 
smooth muscle at all stages of pregnancy (Tuross et al. 1987). 
PGF2α stimulates myometrial contractility, it is also able to initiate parturition in both human 
and animal models. In a human study of oral PGF2α, PGF2α was sufficient to induce labour in 
16 out of 20 women (Karim et al. 1971) whilst a 15-hydroxyprostaglandin dehydrogenase 
hypomorphic mouse, which lack the enzyme responsible for degrading PGF2α, so increasing 
endogenous PGF2α, was able to overcome the progesterone block to initiate pre-term labour 
(Roizen et al. 2008). Investigations of PGF2α ability to induce labour are limited due to the 
lack of clinical need, due to the existence of better drugs, such as oxytocin. As such PGF2α is 
not used clinically to induce labour, rather it is utilised in abortions and for post-partum 
haemorrhage, were long strong contractions are required. 
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While PGF2α may not be the best drug for the initiation of labour, it offers an attractive 
target as a tocolytic, as high PGF2α concentrations correlate with infection induced pre-term 
labour (Mitchell et al. 1978; Sellers et al. 1981; Goldenberg et al. 2000). There are two ways 
in which to inhibit PGF2α; firstly by use of a specific PGF2α receptor (FP) antagonists, or by a 
reduction in its synthesis. Currently there are no specific inhibitors of PGF2α synthesis, 
although experimentally indomethacin, an inhibitor of PGHS-1 and -2 (see prostaglandin 
synthesis), is used to reduced the levels of all prostaglandins. Due to the lack of specific 
inhibitors for PGF2α synthesis, only FP antagonists or transgenic animals lacking the FP 
receptor will be discussed, to ensure that response is due to PGF2α and not other 
prostaglandins.   
In in vitro studies, FP antagonists have been shown to reduce spontaneous contractility, 
while also reducing the amount of force PGF2α is able to produce in pregnant rat myometrial 
tissue (Hirst et al. 2005; Doheny et al. 2007). In human pregnant and non-pregnant, 
spontaneous, oxytocin and phenylephrine-induced contractions showed a significant 
attenuation by the FP antagonist, presumably as a result of inhibition of action of basal 
PGF2α (Friel et al. 2005). These results were repeatable in in vivo studies, were it was shown 
that FP inhibitors reduced spontaneous and PGF2α induced contractility in a dose dependent 
and reversible manner, although in this study oxytocin-induced contractility only shown a 
decreasing trend and failed to reach significance (Chollet et al. 2007; Cirillo et al. 2007). In 
addition to a reduction in contractility profiles, in vivo studies also show a propensity for FP 
antagonists to delay labour, whether that be spontaneous labour, or pre-term labour 
induced by; PGF2α, RU 486 (progesterone antagonists), or lipopolysaccharide (LPS)(via 
inflammation). FP antagonists significantly delayed parturition, culminating in higher birth 
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weight and a higher proportion of live offspring when delivered naturally or by caesarean 
operation performed at expected term (Peri et al. 2002; Hirst et al. 2005; Chollet et al. 2007; 
Cirillo et al. 2007; Goupil et al. 2010).  
A problem with antagonists, is the degree of specificity with which they act. In regard to FP 
antagonists the studies described above were carried out using three different FP 
antagonists, all reportedly FP-specific; PDC113.824, THG113.31 and AS604872, giving 
credence to the suggestions that the effects seen are due to the antagonism of FP rather 
than an off target effect. Similar effects were seen to FP antagonists in a study of mice 
lacking the FP receptor, giving similar results. There has been one study of mice lacking the 
FP receptor, similar to FP antagonists it was found that FP deficient mice were unable to 
deliver pups. Homozygote could become pregnant and gestation occurred normally, but 
parturition failed, although pups could be rescued by caesarean operation shortly before or 
at expected term (Sugimoto et al. 1997). 
While experimentally, inhibition of PGF2α both in vitro and in vivo have resulted in a 
decrease in myometrial contractility and the postponement of labour, to date there has yet 
to be a human clinical trial for an FP antagonists. Although there is currently no data for 
human clinical trials for FP antagonists, in the past inhibitors of PGF2α synthesis have been 
trialled. Unfortunately both PGHS-1 and-2 inhibitors, both upstream synthases of PGs have 
detrimental effects to both mother and foetus (for reviews see London et al. 2000; Olsen 
2005). 
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1.6.1.2     Expression 
The functional effects of PGF2α are dependent upon both the expression of PGF2α, and the 
expression of its receptor, FP. The expression of PGF2α is difficult to investigate. It is 
synthesised and immediately secreted, can both diffuse through lipid bilayers and is 
transported across membranes, and is also rapidly degraded. Due to this, investigations into 
expression have relied upon changes in components of the synthesis and degradation 
pathways. 
While myometrial levels of PGF2α have not been identified, it is known that both amnion and 
uterine venous plasma PGF2α increases in pregnancy, and through gestation (Molnar et al. 
1990a). During birth PGF2α metabolites rise with cervical dilation, continuing to increase 
through early labour into late labour (Mitchell et al. 1978; Sellers et al. 1981). In addition to 
this increase in PGF2α leading to and through parturition, there is also a correlation between 
elevated amniotic PGF2α concentrations and infection associated pre-term labour, 
responsible for around 40% of pre-term births (Mitchell et al. 1978; Sellers et al. 1981; 
Goldenberg et al. 2000). 
 
1.6.1.2.1     Synthesis 
Prostaglandins are not stored within the cell, but rather synthesised and immediately 
secreted when needed.  All five family members are synthesised in a three step process, 
starting from the liberation of arachidonic acid from membranes, oxidation and reduction of 
arachidonic acid to the prostaglandin intermediate PGH2 and finally the conversion from the 
intermediate PGH2 by terminal synthases to the five prostaglandins (see Figure 1.6.1.2.1 for 
overview of PGF2α synthesis).  
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Arachidonic acid, a 20-carbon carboxylic acid, polyunsaturated fatty acid present in 
phospholipids, found in the membranes of cells throughout the body, can be liberated by 
two mechanisms. In the first, phospholipase A2 directly converts phospholipids to 
arachidonic acid, alternatively arachidonic acid can be produced indirectly by PLC. In 
gestation it is the first, phospholipase A2, that is unregulated, allowing for the upregulation 
of the PGs (Zhang et al. 1996; Gibb 1998). 
The second step in the synthesis of prostaglandins is a two-step process, of oxidation and 
reduction, converting arachidonic acid to the intermediate PGH2.  This step is mediated by 
two isoforms of prostaglandin endoperoxide H synthase, PGHS-1 and -2, also referred to as 
cyclo-oxygenase-1 and -2 (COX-1 and -2) (Olson 2003; Tsai et al. 2010). The first step is the 
dioxygenation of arachidonic acid, to give 9-11 endoperoxide and 15-peroxide group, this 
forming the unstable intermediate PGG2 , the 15-peroxide group is then reduced to an 
alcohol forming PGH2 (Smith et al. 2000). PGHS-1 and -2 have dual catalytic capabilities, 
allowing it to act as an endoperoxidase and cyclo-oxygenase activity, with crystallographic 
information showing two distinct binding sites, a peroxidise site and a cyclo-oxygenase site 
(Tsai et al. 2010). They are thought to act as homodimers on the luminal side of the nuclear 
envelope and endoplasmic reticulum membranes, as dissociation of the homodimer, 
inactivates both PSHS-1 and -2 (Xiao et al. 1998; Smith et al. 2000). 
PGHS-1  and -2 are mediated by two distinct genes (Smith et al. 2002) but have high 
homology in their 576 and 587 amino acid sequence, of around 65%, with the residues 
thought to be important for catalysis conserved. Due to the high conservation of PGHS-1 
and -2 they have similar affinities (Km) and capacities (Vmax), but are thought to have 
different physiological effects (Olson 2003). 
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Generally PGHS-1 is constituently expressed, and is referred to as the housekeeping 
enzyme, whereas PGHS-2 is inducible, by pro-inflammatory cytokines amongst others, with 
up to an 80-fold increase (Otto et al. 1995; Hertelendy et al. 2004). In uterine smooth 
muscle there is some debate over the expression and activity of PGHS-1 and -2. It is agreed 
that PGHS-1 levels do not change in pregnancy and labour, PGHS-2 on the other hand has 
been suggested to remain the same, decrease and increase, although more studies suggest 
that activity increases during labour (Moonen et al. 1984; Zuo et al. 1994; Dong et al. 1996; 
Moore et al. 1999; Erkinheimo et al. 2000; Tsuboi et al. 2000).    
The third and final stage of PGF2α production can be achieved in three distinct pathways. 
The principal pathway for PGF2α production is through the reduction of the intermediary 
PGH2 by 9, 11-endoperoxide reductase (prostaglandin F synthase (PGFS)), giving the 
principal 9α, 11α- PGF2α. An alternative pathway culminating in the production in 9α, 11α- 
PGF2α is by reduction from PGE2 by 9-ketoreductase. While the stereoisomer (9α, 11β- 
PGF2α) can be produced from PGD2, by 11-ketoredutase (for reviews see Watanabe, 2000; 
Helliwell et al. 2004). While 9α, 11β- PGF2α, is not the principal PGF2α, it has been shown in 
uterine smooth muscle to result in contractility, similar to its isomer (Giles et al. 1991; 
Mitchell et al. 2005). 
 
 
 
 
 
60 
 
 
 
 
61 
 
1.6.1.2.2     Prostaglandin transport 
Considering the importance of not only PGF2α, but all prostaglandins in physiological 
processes in both health and disease, little investigation has occurred in regard to the 
transport of prostaglandins. It is thought that prostaglandin synthesis starts in the ER, due to 
the localisation of PGHS homodimers on the luminal side of the ER. The product of which 
PGH2, due to its non-polar nature, freely diffuses through the ER membranes, where it is 
converted to the more polar terminal prostanoids in the cytosol. From the cytosol they can 
diffuse freely across the membrane or be transported, this is also the mechanism needed 
for degradation, as little prostaglandin 15-dehydrogenases are found in either the blood or 
plasma (Schuster 1998; Schuster 2002). 
Transport of anions across membranes by diffusion does occur, but at relatively low levels, 
often at a rate too low to maintain biological functions, which is thought to be the case for 
prostaglandins, highlighting the need for a transporter (Schuster 1998). The prostaglandin 
transporter (PGT) is a member of the 12-transmembrane solute carrier organic anion 
transporter2A1 family, (Kanai et al. 1995; Lu et al. 1996; Schuster 1998) which is able to 
mediate both influx and efflux of PGF2α  (Schuster 1998; Schuster 2002; Banu et al. 2003) 
and has been identified in uterine smooth muscle, increasing towards parturition (Banu et 
al. 2005). Unfortunately due to limited studies, PGT in the myometrium and their functional 
role in contractility is at this time unknown. 
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1.6.1.2.3     Prostaglandin degradation 
While synthesis of PGF2α is intimately linked to its effects, the rate of degradation is also 
critical to its biological concentrations, and therefore effects. The first step in PGF2α 
degradation is the oxidation of the 15-hydroxyl group by the NAD+-dependent   15-
hydroxyprostaglandin dehydrogenase (PGDH), giving the biologically inactive 15-keto-13,14-
dihydro PGF2α (Okita et al. 1996) 
There is no or little PGDH activity in the blood or plasma of a number of species, but activity 
is high inside cells. Evidence of this culminated in the suggestion of the two step model of 
metabolic clearance (Schuster 1998; Schuster 2002); suggesting that firstly prostaglandins 
are transported into the cell where they can then be metabolised by PGDH. This has been 
re-created in a number of cellular models, reproducing metabolism of exogenous PGF2α 
(Nomura et al. 2004). 
The levels of PGDH are functionally vital in the myometrium, in maintaining uterine 
quiescent during gestation and initiating parturition. During pregnancy PGDH activity is high, 
which is thought to be due to progesterone, a positive modulator (Greenland et al. 2000). 
While PGDH activity is high in pregnancy, it does not change through gestation, although it 
does drastically decrease in both term and pre-term labour (Giannoulias et al. 2002). The 
importance of a reduction in PGDH in parturition is made clearer when studied in relation to 
pre-term birth. In a study of idiopathic pre-term labour not associated with infection, there 
was a marked reduction in PGDH expression activity within the chorion (Sangha et al. 1994).  
It is the chorion that acts as a barrier between the amnion and the myometrium, and so a 
reduction in chorion PGDH increases myometrial PGF2α (Challis et al. 1999). In addition to 
there being a reduction in idiopathic preterm labour, during infection chorion trophoblasts 
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are destroyed which therefore dramatically reduce PGDH activity, and so PGDH also plays a 
role in infection-induced pre-term birth (Van Meir et al. 1996; van Meir et al. 1997). 
 
1.6.1.3     PGF2α receptor (FP) 
It was originally thought that the prostaglandins directly interact with the cell membranes, 
but due to their differing profiles it was suggested that they interact with receptors and that 
each prostaglandin has its own receptor (Kennedy et al. 1982). With the use of specific 
antagonists these receptors were further characterised, giving the classification that still 
stands today (Coleman et al. 1994). DP receptor for PGD2, IP receptor for PGI2, TP receptor 
for PGTXA2, FP receptor for PGF2α and four EP receptors (EP1-4) for PGE2 . It was determined 
that while each prostanoid binds preferentially to its own receptor, they are able to interact 
with other PG receptors (Coleman et al. 1994). 
The FP receptor has been cloned from a number of species (Abramovitz et al. 1994; 
Sugimoto et al. 1994; Sakamoto et al. 1995) and has been determined to be a G-protein 
coupled receptor, with seven transmembrane domains, an extracellular N-terminal and 
intracellular –COOH, typical of the rhodopsin-type G-protein coupled receptors (Woodward 
et al. 2011). It has a predicted mass of 40 KDa (Sakamoto et al. 1995), and ligand binding 
studies, suggest that PGF2α displays a high affinity (<10nM) binding for its receptor, with a 
Kd of 1.32nM reported from recombinant FP receptors in COS cells  (Coleman et al. 1994). 
The FP receptor has been shown to be a G-protein coupled receptor, functional studies have 
determined that FP is predominantly Gq-coupled, and so through activation of PLC, 
increases DAG and IP3  (Woodward et al. 2011). While this is the predominant pathway, 
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were most of the evidence from uterine smooth muscle points, there has been studies from 
other tissues, suggesting that FP is also coupled G12/G13, activating Rho (Pierce et al. 1999) 
and Gi, MAP kinase pathway (Melien et al. 1998), although this has not been identified in 
uterine smooth muscle. 
Similar to PGHS, expression of the FP receptor change with pregnancy and labour. In human 
pregnancy expression decreases by 45% compared to levels found in non-pregnant 
myometrium, while levels were higher in labouring samples (Matsumoto et al. 1997; Brodt-
Eppley et al. 1999). There is also a correlation between high FP receptor levels in pre-term 
birth, with higher levels found in pre-term birth with and without labour compared to term-
pregnancy without labour (Brodt-Eppley et al. 1999). Similar to human tissue, rat 
myometrial FP receptor expression increases significantly from late gestation until delivery, 
returning to pre-partum levels by one day post-partum (Brodt-Eppley et al. 1998; Al-Matubsi 
et al. 2001). This leads to the suggestion that FP receptors play a pivotal role in the 
maintenance of quiescence during gestation and the initiation of parturition. While FP 
receptors obviously play a vital role, the mechanism of regulation in the myometrium is 
currently unknown. 
 
 
1.6.1.4     Proposed mechanism of action  
The importance of PGF2α is in no doubt, there have been numerous studies regarding its role 
in both normal physiology and pathological conditions. As such it is surprising what little 
information is known regarding its mechanism of action, especially in the myometrium.   
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Due to the importance of [Ca2+]i in the contractility of the uterus, it is hardly surprising that 
both intracellular and extracellular Ca2+ sources have been shown to be important to the full 
effects of PGF2α (Parkington et al. 1999; Coleman et al. 2000; Ruttner et al. 2002). Although 
the relative contributions are still debated; some studies suggest only extracellular Ca2+ is 
needed (Molnar et al. 1990b; Perusquia et al. 1992), while others show release from the 
store that is adequate to cause contraction (Reiner et al. 1976; Villar et al. 1986). This 
release from the store is thought to be mediated through an increase in IP3, through the 
pertussis insensitive Gq (Maka et al. 1993; Phaneuf et al. 1993; Phillippe et al. 1997) known 
to associate with the FP receptor (Coleman et al. 1994) although again there is some 
controversy that the amount of IP3 produced by PGF2α is enough to result in adequate 
release from the store (Molnar et al. 1990b; Molnar et al. 1995). 
Besides the importance of both intracellular and extracellular Ca2+, of which there is debate 
regarding relative contributions, Ca2+ sensitisation has also been suggested to be the cause 
of PGF2α increase mechanical output in uterine smooth muscle, although again these studies 
are limited, and do not look at the mechanisms of Ca2+ sensitisation (Izumi et al. 1996; 
Woodcock et al. 2006). Another way in which PGF2α exerts its affects is through 
depolarisation, PGF2α causes depolarisation, consisting of a slow wave of depolarisation, 
dependent on Na+, followed by a fast train of action potentials, which is dependent on Ca2+  
(Reiner et al. 1976). Again the mechanism of this depolarisation is as yet unresolved.  
Limited studies have also suggested the involvement of ROC and influx of Ca2+  (Coleman et 
al. 2000). PGF2α has also been suggested to result in a reduction in cAMP, although this is 
highly controversial, based on two studies; the first reporting a reduction in IBMX induced 
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cAMP by PGF2α (Goureau et al. 1990) whilst the second reported that cAMP was not 
attenuated by PGF2α (Molnar et al. 1987). 
While the mechanisms of PGF2α have not been studied in detail, it is probable that like many 
agonists, PGF2α works through multiple mechanisms synergistically to increase myometrial 
mechanical output. To date the mechanisms involved in PGF2α response and their relative 
contributions are unknown.   
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1.7     Summary 
In summary, the uterus is a spontaneously active muscle under myogenic control, 
modulated by hormonal stimuli. One of the critical hormones involved in parturition is PGF2α.  
Without PGF2α parturition does not occur, while high levels correlate with pre-term birth, 
especially those caused by infection. While the functional role of PGF2α as a uterotonic is 
understood, the mechanism by which it is able to increase mechanical output of myometrial 
tissue is unresolved. 
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1.8     Aims 
The broad stroke of my study was to examine the force Ca2+ relationship in response to 
PGF2α in late gestation pregnant rat uterine smooth muscle.  
Specific aims of this study were: 
 To determine the relationship between force and Ca2+ in pregnant rat myometrium 
in control conditions. 
 To study the force Ca2+ relationship induced by PGF2α compared to those in control 
conditions. 
 To study the mechanism of PGF2α, specifically the role of Ca
2+ release from the store, 
and Ca2+ entry pathways. 
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Chapter 2 
Materials and methods 
 
2.1    Tissue preparation  
Wistar rats were chosen as our model because they have been regularly used in our 
laboratory and have little variation in gestation. Virgin females were mated on day 0 (PM), 
and humanely killed by cervical dislocation under CO2 anaesthesia on day 22 (AM), full term, 
in accordance with UK Home Office legislation. Once neonates were removed, uterine horns 
were dissected and carefully cleaned. Uterine tissue was kept in physiological saline solution 
(PSS) for the remainder of time, unless otherwise stated. 
 
2.1.1     Longitudinal myometrial strips 
Uterine tissue was pinned to the bottom of an agar-filled petri dish and with the use of 
forceps and scissors, small strips of the appropriate length, of longitudinal muscle layer 
were removed from the underlying circular smooth muscle layer and endometrium. 
Longitudinal muscle strips were loaded with the appropriate Ca2+ sensitive indicators, Indo-1 
AM or Fluo-4 AM, for measuring [Ca2+]i using photometric or confocal imaging systems, 
respectively, combined with simultaneous force recordings. 
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2.1.2    Cell isolation 
Longitudinal myometrial strips from the freshly obtained uterus were cut into small pieces 
and incubated in 2ml modified Hanks balanced salt solution (HBSS) (see composition below); 
for 30 min at 36°C with gentle agitation and changing the solution twice. 
Enzyme digestion was achieved with Liberase Blendzyme 3 (0.28 Wunsch/ml); 5ml modified 
HBSS; for 50-60 minutes, at 36°C with gentle agitation. After enzyme digestion strips were 
removed and washed thoroughly in modified Kraft-Brühe (KB) media (for composition of KB 
media see below). Tissue was then incubated for 30mins in 1.5ml KB media at room 
temperature. Trituration was begun with a fire polished glass Pasteur pipette with 2mm 
diameter tip, the suspension obtained was filtered on a 20µm nylon mesh. Freshly isolated 
myocytes were kept in KB media until loaded with Fluo-4, not exceeding 4 hours. 
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2.2     Measuring isometric force 
To investigate contractility, longitudinal tissue strips of approximately 1 x 2 mm were 
clamped by two aluminium foil clips at both ends, transferred to a small organ bath (500 µl) 
and fixed to the bottom of experimental chamber at one end and with a Fort10g isometric 
force transducer (WPI, Hertfordshire, UK) at the other (Figure 2.2a). PSS or appropriate 
solutions were perfused at 3.5 ml/min through a magnetic valve controlled gravity fed 
system of syringes and heated to 36.5°C throughout (Figure 2.2b). 
Passive tension was set by use of a reference high-K+ solution (40 mM KCl). Passive tension 
was set at 50 % of high-K+ peak mechanical response, tissue was left until spontaneous 
contractions became regular and stable. If the tissue failed to spontaneously contract after 
60 minutes, but was responsive to high-K+, it was classified as quiescent.  
In all protocols an initial 40 second application of high-K+, the initial amplitude of which was 
used to normalise both force and Ca2+ data, taken for 100%. Tissue was left to stabilise for at 
least 10 minutes after high-K+ induced response before start of experiments. 
Electrical signals from the force transducer were amplified and recorded by axon CNS 
datadigi 1440A data digiboard (Scientifica, Sussex, UK), using Axon software (Axoscope 
version 10.0, Molecular devices, Berkshire, UK), at a sampling rate of 1 kHz (Figure 2.2b), 
and measured in mN.  
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2.3     Measuring [Ca2+]i 
 
2.3.1     Photometric system, Indo-1 
Indo-1 AM was chosen as the Ca2+ indictor for simultaneous force [Ca2+]i measurements on 
the photometric system. Optimisation of indo-1 AM concentration was determined to be 
12.2µM, loaded for 3 hours 30 minutes at room temperature. In these conditions complete 
hydrolysation of the AM ester occurred, without excessive formaldehyde accumulation. The 
use of indo-1 AM did not compromise tissue function, gave a good signal, which lasted for 
the duration of the experiment (2 hours). 
Indo-1 AM (50µg) was prepared in a solution of 50 µl DMSO containing 12.5mg pluronicF-
127, added to 4ml PSS. 5 myometrial strips were incubated into 2ml of the indo-1 PSS for 3 
hours 30 minutes at room temperature, with gentle agitation. 
Ca2+ measurements were obtained for the ratio of emission wavelengths of 400nm and 
500nm, while excited at 355nm. Excitation of 355nm was provided by xenon lamp and 
monochromator graticule (Cairne, Kent, UK), and focused on the sample with x10 (N.A. 0.30) 
objective (Olympus, Essex, UK), whilst the two emissions wavelengths were detected by 
photomultiplier tubes (Cairne, Kent, UK), and amplified and converted to a digital signal by 
axon CNS datadigi 1440A data digiboard (Scientifica, Sussex, UK). Signals were recorded at a 
sampling rate of 1 KHz, using Axoscope software (version 10.0, Molecular devices, Berkshire, 
UK) (Figure 2.3.1.1). A typical example of changes in fluorescence measured at 400nm and 
500nm and their ratio is shown in Figure 2.3.1.2.  
75 
 
Due to the difficulties in calibrating [Ca2+]i for each individual experiment, all Ca
2+ analysis is 
expressed as a percentage of initial high-K+ response, unless otherwise stated. Additionally it 
was not confirmed that the fluorescent indicator was not saturated during experiments, this 
could have been achieved with the addition of high concentration of Ca2+ to the bathing 
solution at the end of experiments. While saturation was not tested, this would not have 
been an issue in the majority of experiments, as analysis was completed at lower than 
maximum [Ca2+]i within the experiment. For experiments analysed at the top of Ca
2+ trace, 
deep spikes remained, suggesting that the signal was not saturated.  
For simultaneous measurement of force and [Ca2+]i the experimental apparatus for force 
measurement previously described can be place on the stage of an inverted microscope, 
with the use of a glasscoverslip as the bottom of the chamber, both excitation and emission 
wavelengths can pass through, allowing for the simultaneous measurement of both force 
and [Ca2+]i. Data from Ca
2+ recording and force is routed to the same data digiboard and 
recorded simultaneously using Axoscope software (Figure 2.3.1.3) 
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2.3.2    Confocal microscopy, Fluo-4 
 
2.4.2.1    Myometrial strips  
Fluo-4 AM was used as the Ca2+ sensitive fluorescent indicator for all confocal microscopy 
work. Optimisation of Fluo-4 AM concentration for myometrial strips was determined to be 
22.2μM, loaded for 3 hours. In these conditions complete hydrolysation of the AM ester 
occurred, without excessive formaldehyde accumulation. The use of Fluo-4 AM did not 
compromise tissue function, gave a good signal, which lasted for 2-3 hours. 
Fluo-4 AM (50µg) was prepared in a solution of 50 µl DMSO containing 12.5mg pluronicF-
127, added to 2ml PSS. 5 myometrial strips were incubated in 1 ml of the Fluo-4 PSS for 3 
hours at room temperature, with gentle agitation. 
Ca2+ measurements were obtained by use of a Nipkow discbased, confocal imaging system 
(PerkinElmer, MA, USA), connected to a sensitive iXon cooled charge-coupled device camera 
(Andor technology, Belfast, UK). Excitation was provided by an argon 488/568nm laser 
(PerkinElmer, MA, USA), at 488nM and focused by x20 objective (N.A. 0.72). Images were 
collected at 30 frames per second using Andor iQ software (Andor technology, Belfast, UK). 
(Figure 2.3.2) 
For simultaneous measurement of [Ca2+]i and force, one end of the strip was attached to a 
Fort10g isometric force transducer, the other to a fixed hook. Mechanical signal was 
recorded by another computer as previously described. 
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2.4.2.2    Isolated cells  
Optimal concentration of Fluo-4 AM for isolated cells was determined to be 2.5µM, loaded 
for 20 minutes at room temperature. In these conditions complete hydrolysation of the AM 
ester occurred, without excessive formaldehyde accumulation. The use of Fluo-4 AM did not 
compromise cellular function, gave a good signal, which lasted the duration of the 
experiment. 
1 mM stock Fluo-4 was prepared by addition of 46µl DMSO to 50µg aliquot Fluo-4 AM. 
Indicator was prepared by addition of 5µl DMSO containing pluronicF-127 acid (50mg 
pluronic acid plus 200 µl DMSO) to 5µl 1mM Fluo-4 to 2ml cell suspension, giving a final 
Fluo-4 AM concentration of 2.5µM. Cell suspension was then incubated at room 
temperature on the stage of a confocal microscope for 20 minutes, allowing cells to adhere 
to the glasscoverslip, after which time cells were slowly perfused with PSS solution. 
Measurement of [Ca2+]i was the same as used for myometrial strips. Again Confocal images 
were collected at 30 frames per second using x60 water objective (N.A. 1.25) (Olympus, 
Essex, UK). 
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2.5     Analysis and statistics 
The software used to analyse data was OriginPro 8.6 (OriginLab corporation, Northampton, 
MA, USA). Statistics were performed in SPSS statistics 19 (IBM, Hampshire, UK). Distribution 
of data was determined by use of Shapiro-Wilk test and analysed using either paired-
samples t-test or independent-samples t-test or the non-parametric versions; Wilcoxon 
signed rank test or Mann-Whitney U test. Statistical significance was taken as p < 0.05, with 
individual p values given in parentheses. The data is given as mean ± S.E.M or median ± 
I.Q.R. as appropriate, with ‘n’ representing the number of experiments on different animals, 
unless otherwise stated.  
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2.6     Solutions and Chemicals 
All chemicals from Sigma Aldrich (Gillingham, UK) and pH to 7.40 with 4M NaOH and 1M HCl 
as needed, unless otherwise stated. 
 
Physiological saline solution (krebs): Freshly made, to the following constituents: 
 NaCl, 154 mM 
 KCl, 5.6mM 
 MgSO4, 1.2mM 
 HEPES, 10.9mM 
 Glucose, 11.7mM 
CaCl2, 2mM 
High potassium solution (40mM KCl): Freshly made, to PSS recipe with isosmotic 
substitution of NaCl for KCl.  
 NaCl, 119.6mM 
KCl, 40mM 
Modified Kraft-Brühe (KB) media: Freshly made, to the following: 
 KCl, 40mM 
 K2HPO4, 10mM 
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 Taurine, 10mM 
 TES, 10mM 
Sucrose, 11mM 
Pyruvate, 5mM 
Creatine, 5µM 
EGTA, 50µM 
K-glutamate, 100nM 
BSA/ albumin, 1mg/ml 
Stock immediately frozen -20˚C, used within 2 weeks. 
Zero Ca2+ physiological saline solution (0Ca2+): Substitution of CaCl2 with 2mM of the Ca
2+ 
chealator ethyl glycol-bis (β-aminoethyl ether)-N,N,N’,N’-tetra acetic acid (EGTA).  
Modified physiological saline solution: Substitution of MgSO4 for MgCl2 (1.2mM), needed 
for Gd3+ and La3+ experiments, as MgSo4 will precipitate out. 
Modified zero Ca2+ physiological saline solution: Substitution of MgSO4 for MgCl2 (1.2mM), 
needed for Gd3+ and La3+ experiments, as MgSO4 will precipitate out. 
Modified Hanks balanced salt solution (HBSS): Made daily Ca2+-free and Mg2+-free HBSS 
(Life technologies, Paisley, UK) 40µM Ca2+ 1mg/ml albumin BSA. 
Adenosine triphosphate (ATP): Reconstituted in dH20 for a stock concentration of 10mM 
daily, working concentration 100µM prepared in PSS/0Ca PSS. 
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Carbachol (CCh): Reconstituted in dH20 for a stock concentration of 100mM stored at +4°C, 
for maximum 4 months (efficacy previously confirmed in the laboratory). Working 
concentration of 100µM prepared in PSS/0Ca PSS.  
Cyclopiazonic acid (CPA): Reconstituted in DMSO for stock concentration of 20mM stored at 
+4°C, working concentration of 20µM prepared daily in PSS/0Ca PSS/nifedipine. 
Gadolinium (Gd3+): Fresh 1mM stock concentration of GdCl3 dH20 prepared freshly when 
required, diluted to working concentration of 10µM in modified PSS/modified 0Ca PSS. 
Lanthanum (La3+): Fresh 10mM stock concentration of LaCl3 dH20 prepared daily when 
required, diluted to a working concentration of 10µM in modified PSS/modified 0Ca PSS. 
Liberase Blendzyme 3: Reconstituted to manufactures instruction in HBSS, to 14 
Wünsch/ml. Working concentration 0.28 Wünsch/ml in modified HBSS. (Roche Applied 
Science, Mannhein, Germany) 
Nifedipine: Reconstituted in ethanol to a stock concentration of 10mM, stored at +4°C in 
dark. Working concentration 10µM prepared in appropriate solution. 
Prostaglandin F2α: Stock concentration 1mM reconstituted in dH20, aliquots stored at -20°C. 
Thawed aliquots stored at 4°C for a maximum of 5 days, diluted in appropriate solution for 
working concentrations of between 10nM - 5µM.  
18-β-glycyrrhetinic acid (18-β-GA): Reconstituted in DMSO for a stock concentration of 
50μM stored at +4°C, working concentration 50nM prepared in PSS. 
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Chapter 3 
 
Ca2+ and contractility profiles in late gestation pregnant rat 
myometrium 
 
 
3.1     Introduction 
Ca2+ plays a pivotal role in the production of force in uterine smooth muscle. An increase in 
[Ca2+]i occurs either through Ca
2+ influx via VOCC or release from the SR. Ca2+-calmodulin 
activates MLCK, leading to the phosphorylation of myosin light chains (MLC20), resulting in 
activation of cross-bridge cycling and the production of force. Relaxation occurs upon 
dephosphorylation of MLC20-P cross bridge cycling can no longer occur and force therefore 
falls.  
In spontaneously active rat longitudinal myometrium, the increase in [Ca2+]i results primarily 
from influx through VOCC (L-type Ca2+ channels) during the action potential (Shmigol et al. 
1998b). Spike like action potentials (AP) are generated by an influx of Ca2+ through VOCC in 
addition to an increase in permeability to Na+ (Shmigol et al. 1998b) peaking within 
approximately 10ms, after which repolarisation occurs, due to, voltage-, time- and Ca2+-
dependent inactivation of VOCC along with activation of voltage- and Ca2+-dependent K+ 
channels (Mironneau et al. 1980; Mironneau et al. 1981).  
The mechanism of initiation of action potentials in the myometrium has not been 
elucidated, and as yet pacemaker cells have not been identified. It is thought to involve the 
rhythmic alteration in basal membrane potential, termed slow waves, that are seen in 
smooth muscle cells of myometrial tissue, although again the underlying ionic mechanism 
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responsible for this is yet to be fully resolved (Casteels et al. 1965; Sanborn 1995). Once 
membrane potential of the slow wave reaches threshold potential, a train of fast spike-like 
action potentials are generated on top of the slow wave (Kuriyama et al. 1976). It is this 
train of action potentials that generate Ca2+ spikes and force (Burdyga et al. 2009). 
The duration of the train of action potentials and the frequency within each burst controls 
intracellular Ca2+ and thus is responsible for the control of myometrial contractility. Within a 
train of action potentials, a single action potential is associated with single Ca2+ spike and 
brief phasic contraction (Burdyga et al. 2009). During the burst of action potentials which 
result in a burst of Ca2+ spikes the phasic contractions due to slower kinetics of relaxation 
summate and produce complex titanic like phasic contractions (Mironneau 1973; Shmigol et 
al. 1998b). Depending on the frequency of action potentials (Ca2+ spikes) this results in 
either incomplete tetanus, where notches in force can easily be seen within the complex 
phasic contraction, or at higher frequencies of action potential mediate smooth titanic-like 
phasic contractions. Thus, the force produced is as a result of summation of individual 
phasic contractions associated with each action potential mediated Ca2+ spike (Mironneau 
1973; Burdyga et al. 2009). 
While the total contraction is dependent on the duration and frequency of trains of action 
potentials within the burst, it is also dependent on the ability of the tissue to propagate the 
action potentials between the smooth muscle cells via gap junctions and synchronise 
contraction of multiple muscle bundles. In the myometrium as in other phasic smooth 
muscles gap junctions provide the electrical communication between uterine smooth 
muscle cells (Cole et al. 1985). During gestation and in the non-pregnant uterus the density 
of  gap junctions is low which is thought to ensure the limitation in spatial spread of action 
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potentials, which results in poor electrical coupling between smooth muscle cells and 
asynchronous activity leading to the maintenance of quiescence throughout gestation 
(Lammers et al. 1994). Towards the end of gestation and parturition, propagation of action 
potentials and velocity of conduction increases, due to an increase in the density of gap 
junctions, improving the synchronous activity needed to maximise recruitment of the 
muscle bundles to expel the foetus (Cole et al. 1985; Lammers et al. 1994; Doring et al. 
2006). 
The aim of this chapter was to characterise the force / Ca2+ relationship in longitudinal 
myometrial strips isolated from late gestation rat myometrium by simultaneous recording of 
[Ca2+]i and force on small (1 x 2 mm) longitudinal myometrial strips loaded with the Ca
2+ -
sensitive indicator Indo-1. 
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3.2     Material and methods 
Tissue 
Longitudinal myometrial strips (1x 2 mm) from the ovarian portion of 22 day gestation 
Wistar rats were used throughout, obtained as described in Chapter 2. 
Simultaneous measurements of force and [Ca2+]i  
Simultaneous measurements of force and [Ca2+]i was achieved, using photometric system as 
previously described (see Chapter 2 for details). Tissue strips were continuously perfused 
with PSS until stable spontaneous activity was observed or tissue classified as quiescent, if 
spontaneous activity did not start in 60 min. After a period of stable contractility and high-K+ 
responses, PSS containing nifedipine (10µM) or 18-β-glycyrrhetinic acid (18-βGA) (50nM) 
was applied, to investigate the role of L-type VOCC in the control of Ca2+ signalling and 
contractility and gap junctions in spreading these signals in intact uterine strips, 
respectively. 
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3.3     Results 
 
3.3.1     Contractility profiles found in late gestation pregnant rat myometrium 
Based on numerous observations it was established that uterine tissue strips could either be 
spontaneously active or quiescent. Spontaneously active strips could be further divided into 
two subgroups, strips with regular and stable phasic contractions and those showing 
irregular contractions (Figure 3.3.1.2 & 3.3.1.3). 
Quiescent uterine strips readily responded with an elevation of [Ca2+]i and force to brief (40 
s) application of high-K+ (40mM KCl) depolarising solution. High-K+ induced a sustained 
increase in [Ca2+]i superimposed by Ca
2+ spike oscillations which was associated with a 
concomitant production of force. Removal of high-K+ resulted in restoration of resting [Ca2+]i 
and relaxation of force (Figure 3.3.1.1). 
The spontaneously active uterine strips with irregular activity showed a large variation in the 
number of Ca2+ spikes which could easily be distinguished with each spike correlating well 
with a brief phasic contraction. Typical example is shown in figure 3.3.1.2 which 
demonstrates an extreme case of irregular activity. Whilst Ca2+ spikes and phasic 
contractions were stereotypical in the tissue samples with irregular type of activity there 
was great variability in the frequency of Ca2+ spikes and contractions which were always 
submaximal in amplitude due to low frequency of Ca2+ spikes (data not shown). 
Spontaneously phasic active tissue reached stable activity within 90 minutes and once 
stabilised, the amplitude, duration and frequency were maintained throughout the rest of 
the experiment. Average amplitude of spontaneous contractions was 68.94 ± 3.46 % of peak 
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high-K+, with the average duration of 14.67 ± 2.35 s and a frequency of 4.98 ± 1.66 
contractions per 5 minutes. There was a high variability in the amplitude of spontaneous 
contractions compared to the amplitude of peak high-K+ contracture, which was taken for 
100 %. Contractions were associated with the burst of Ca2+ spikes which showed little 
variability in the amplitude within the complex Ca2+ transient. As a rule the frequency of 
Ca2+ spikes was highest at the beginning of each burst and towards the end of the 
contraction Ca2+ spikes slowed and ceased and [Ca2+]i returned to basal levels followed by 
relaxation (Figure 3.3.1.3b).  
All three contractility patterns, responded to high-K+ depolarisation. In quiescent and phasic 
spontaneously active tissue, this usually was initiated by a fast increase in [Ca2+]i , [Ca
2+]i 
often fell slightly as a result of both voltage- and time- dependent inactivation of L-type 
VOCC. When high-K+ solution was replaced with physiological saline solution there was 
often  see a brief burst of  rebound action potential mediated  Ca2+ spikes  which  result  
from  reactivation of the inactivated voltage gated Ca2+ channels during the repolarisation 
phase caused by restoration of normal K+ in the bathing solution. Whilst all three 
contractility profiles differ in the patterns of Ca2+ transients, it was evident from these 
experiments that for all types of strips the Ca2+ spikes were a key mechanism controlling the 
production of force in pregnant rat myometrium.  
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3.3.2    Role of voltage activated Ca2+ channels in spontaneous and quiescent myometrial 
tissue 
The role of VOCC in myometrial activity was determined by use of the L-type Ca2+ channel 
inhibitor nifedipine (10µM) (n = 5). Addition of nifedipine to spontaneously active tissue 
resulted in the quick and complete abolishment of both force and Ca2+ transients (Figure 
3.3.2a). In addition, pre-treatment of spontaneously active or quiescent uterine strips with 
nifedipine fully blocked high-K induced increase in [Ca2+]i and force (Figure 3.3.2b). These 
experiments indicate the key role of VOCC in control of both spontaneous contractions and 
those induced by high-K+ depolarisation. 
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3.3.3     The effects of inhibition of gap junctions by 18-β-glycyrrhetinic acid  
To investigate the role of gap junctions in control of Ca2+ signalling and force in 
spontaneously active myometrial strips, the effects of the gap junction inhibitor, 18-β-
glutherhinic acid (18-β-GA) on Ca2+ transient and force in uterine smooth muscle was 
investigated.  These experiments were performed using confocal microscopy combined with 
force measurements. These experiments showed that inhibition of gap junctions by 18-β-GA 
resulted in a decrease in the frequency of Ca2+ spikes and concurrent decrease in the force 
of spontaneous contractions, similar to those seen in  strips with irregular contractile 
activity  (Figure 3.3.3) (n=1). Although it was not regularly studied it was clearly seen that 
there was a significant decrease in the speed of inter-bundular propagation of the Ca2+ 
spikes which was associated with poor recruitment of the muscle bundles and decrease in 
the mechanical output (data not shown).  While further work is needed to confirm these 
results, it is evident that gap junctions are needed to propagate Ca2+ spikes allowing for the 
whole tissue to control recruitment and coordination of the mechanical activity of the 
uterus. 
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3.4     Discussion 
Contractility in uterine smooth muscle is dependent on trains of spike like APs, concurrent 
Ca2+ spikes, caused by Ca2+ entry through L-type Ca2+ channels, that control the mechanical 
activity (Mironneau 1973; Shmigol et al. 1998b). Our simultaneous recordings of force and 
[Ca2+]i of spontaneous or high-K
+ evoked activity in late gestation pregnant rat myometrium 
are in good agreement with these early electrophysiological observations. It can be clearly 
seen that the working unit in uterine smooth muscle is a Ca2+ spike which control brief sub-
maximal phasic contractions. Clustering of the Ca2+ spikes in a burst and intracellular 
propagation of the Ca2+ spikes allows the production of large complex phasic contractions 
(Figure 3.3.2) (Burdyga et al. 2009) 
Spontaneous uterine contraction has been shown to be primarily dependent on influx of 
Ca2+ via L-type VOCC (Shmigol et al. 1998b). This dependence on L-type VOCC could be seen 
on both spontaneous and quiescent tissue, were the application of the L-type Ca2+ channel 
inhibitor nifedipine resulted in the complete abolishment of both spontaneous and high-K+ 
induced Ca2+ transient and force.  
While the production of force is dependent on the frequency of action potentials and 
therefore the frequency of Ca2+ spikes, it is also dependent on the propagation of the signal 
through the tissue (Lammers et al. 1994). The better synchronised the tissue is, the more 
myometrial bundles will be recruited to contribute to the contraction, thus increasing the 
capacity of force that is able to be produced. The propagation of contractions is due to the 
presence of gap junctions (Lammers et al. 1994). Inhibition of gap junctions by 18-β-GA 
resulted in a loss of synchronisation of Ca2+ signalling among the muscle bundles which 
resulted in a decrease in force production due to a decrease in the number of bundles 
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recruited during a contraction, reinforcing the importance of myometrial gap junctions in 
the normal functioning of uterine smooth muscle.   
These properties of myometrial contractility can account for the three types of spontaneous 
activity found in pregnant rat longitudinal smooth muscle; normal phasic activity, irregular 
activity and quiescent activity. Perhaps the easiest way to explain the quiescence in strips 
which responded to high-K+ depolarisation was lack of pacemaker activity within the small 
strip. Lack of pacemaker is most likely responsible for the majority of quiescent samples, 
were high-K+ stimulation caused a normal response. Under the influence of high-K+ induced 
depolarisation, pacemaker activity is not needed as depolarisation induced by high-K+ 
always reaches threshold of activation of VOCC in all bundles (Jmari et al. 1986), and there is 
no need for the Ca2+ signal to propagate. Thus, irrespective of its initial activity all uterine 
strips respond to high-K+ stimulation with maximal response. 
Irregular activity, similar to quiescent tissue, can be either due to low electrical activity or 
poor electrical communication between the muscle bundles. Unlike quiescent tissue, it is 
more likely to be due to asynchronous activity. Frequency of Ca2+ spikes representing 
individual action potentials was very low and could easily be distinguished, which correlated 
well with brief phasic contractions. The low frequency of Ca2+ spikes were responsible for 
the irregular and low amplitude contractions which was similar to the effects of the gap 
junction inhibitor 18-βGA. 
Compared to quiescent tissue and tissue with irregular activity, spontaneously active tissue 
has normal pacemaker activity and is well synchronised, to give regular and spontaneous 
contractions. In this tissue it can be clearly demonstrated, as shown in figure 3.3.1.3 that 
while force is increased under high-K+ stimulation the amplitude of the Ca2+ transient of 
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PGF2α induced contraction did not change compared to control, emphasising the importance 
of frequency of Ca2+ spikes being responsible for the amount of force produced (Mironneau 
1973; Burdyga et al. 2009). The increase in force seen with high-K+ stimulation, is probably 
due to better recruitment of myometrial bundles, higher frequency of Ca2+ spikes and 
sustained rise of [Ca2+]i compared to control contractions. While this occurs in many cases, it 
is not universal, those strips with good synchronicity had spontaneous contractions of the 
same amplitude as high-K+ induced contractions. 
It has been demonstrated that myometrial tissue is able to respond in three characteristic 
ways under normal physiological experimental conditions, and our data agree and add to 
the well known mechanisms which control myometrial contractility. After setting up the 
techniques my next goal was to use current techniques and investigate possible 
mechanisms involved in stimulant action of PGF2α on Ca
2+ signalling and force in longitudinal 
uterine smooth muscle cells. 
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Chapter 4 
 
The effects of prostaglandin PGF2α on force / Ca
2+ relationship in 
pregnant rat myometrium 
 
 
4.1     Introduction 
The importance of temporal and spatial characteristics of [Ca2+]i in control of spontaneous 
myometrial contractility has previously been discussed (Chapter 3). A number of possible 
mechanism have been suggested to be responsible for the increase in myometrial output 
produced by different agonists which include; a) an increase in [Ca2+]i (Molnar et al. 1990b), 
b) an increasing in the frequency of AP/ Ca2+ spikes (Burdyga et al. 2009) or c) Ca2+ 
sensitisation (Izumi et al. 1996). 
Previous studies have clearly shown that PGF2α increases uterine smooth muscle contractile 
output in all species studied (Reiner et al. 1976; Tuross et al. 1987; Beretta et al. 2004). The 
increase in myometrial force seen with PGF2α is dose dependent, whilst sensitivity increases 
throughout gestation (Crankshaw et al. 1992). The relationship between [Ca2+]i and force 
induced by PGF2α is unknown and requires further investigation. 
Based on force studies, the importance of both external and intracellular Ca2+ in the effects 
of PGF2α have been shown (Perusquia et al. 1992). The importance of Ca
2+ signalling was 
validated with the measurement of [Ca2+]i, also suggesting that both intracellular and 
extracellular Ca2+ are required for the full response of PGF2α (Ruttner et al. 2002). Whilst the 
importance of Ca2+ to the full effects of PGF2α is in no doubt, there are conflicting reports  as 
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to the mechanism of this, some studies suggest an increase in [Ca2+]i  (Molnar et al. 1990b) 
while others report it remains unchanged (Woodcock et al. 2006). The importance of Ca2+ 
has not been resolved due to the limited investigations of simultaneous force and [Ca2+]i  
(Phillippe et al. 1997; Parkington et al. 1999). In addition to the confusion remaining over 
the relationship between [Ca2+]i and force, Ca
2+ sensitisation has also been suggested to be, 
at least part of the mechanism behind PGF2α (Izumi et al. 1996; Woodcock et al. 2006). 
Prostaglandins, especially PGF2α are known to have major roles in pregnancy and labour. 
PGF2α is a known uterotonic, and inhibition results in delayed parturition (Peri et al. 2002; 
Kawamata et al. 2008; Goupil et al. 2010). While the functional effects have been 
thoroughly investigated in a number of species, mechanistic data are limited, especially 
those directly examining the relationship between force and [Ca2+]i. It is therefore the aim of 
this study, to examine the effects of PGF2α on Ca
2+ signalling and force and investigate its 
possible mechanism. 
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4.2     Materials and methods 
 
Tissue 
Longitudinal myometrial strips (1x 2mm) from the ovarian portion of 22 day gestation 
Wistar rats were used throughout, obtained as described in chapter 2. 
Simultaneous measurements of force and [Ca2+]i  
Simultaneous measurements of force and [Ca2+]i was achieved using a photometric system 
as previously described (see Chapter 2 for details). Tissue was continuously perfused with 
PSS until stable contractility was achieved or tissue classified as quiescent. After a period of 
stable contractility and high-K+ response, 50nM PGF2α was applied for 5 minutes. 50nM 
PGF2α was determined as optimal concentration based on preliminary non-cumulative 
concentration response experiment. 50nM PGF2α was determined to be the optimal 
concentration as it was the lowest concentration to give a significant increase in phasic 
contractility; amplitude, duration and frequency. 
Analysis and statistics 
Analysis was achieved in Origin 8.6. The following force and Ca2+ parameters were 
measured; amplitude, duration, frequency and baseline, over the five minutes treatment 
time compared to five minutes control contractions. For force, amplitude was taken at 50 % 
duration and expressed as a percentage of peak high-K+, duration measured at 50 % 
amplitude, frequency was the number of contractions within the five minute treatment 
period and basal force as the average baseline in the 5 minutes. Ca2+ was measured similar 
to force, except for amplitude of Ca2+ which due to photobleaching, was measured as the 
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last 2 contractions in the control period to the first 2 PGF2α contractions, while frequency of 
Ca2+ spikes was determined for the initial 10 seconds of contractions. 
Distribution of data was determined by use of Shapiro-Wilk test. Paired t-test or Wilcoxon-
signed rank test were used to determine the effect of PGF2α. Data is expressed as mean ± 
S.E.M. or median ± I.Q.R. as appropriate. 
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4.3     Results 
 
4.3.1    The effects of prostaglandin PGF2α on force / Ca
2+ relationship on spontaneously 
active pregnant rat myometrium 
 
The effects of PGF2α were investigated on indo-1 loaded longitudinal myometrial strips from 
late gestation rat which were either spontaneously active or quiescent. On spontaneously 
active tissue PGF2α resulted in two responses; either an increase in phasic contractility or a 
sustained rise in force for the period of agonist application (Figure 4.3.1.1 & 4.3.1.2). 
PGF2α increased phasic activity in 7 out of 12 spontaneously active samples (Figure 4.3.1.1). 
Amplitude of contractions increased from 72.27 ± 4.83 % of peak high-K+ response to 98.39 
± 5.420 % (p=0.001); duration from an average of 12.23 ± 4.78 s to 16.54 ± 11.61 s (p=0.028) 
and frequency from 4.98 ± 1.66 contractions / 5 min to 7.19 ± 1.44 contractions (p=0.003). 
Additionally there was an increase in basal force upon application of PGF2α, increasing from 
1.48 ± 2.25 % of peak high-K+ to 4.79 ± 6.83 % (p=0.018) (Figure 4.3.1.1).  
It has previously been shown for uterine smooth muscle that contractions are the result of 
changes in [Ca2+]i (Longbottom et al. 2000; Burdyga et al. 2009), it is therefore important to 
investigate changes in [Ca2+]i and how they correlate with force in the presence of PGF2α. As 
expected each phasic contraction had an associated Ca2+ transient. As with force, the 
duration and frequency of the Ca2+ transients increased with the addition of PGF2α, duration 
increased from 15.80 ± 4.43 s to 21.32 ± 5.49 s (p=0.0019), whilst frequency increased from 
4.97 ± 0.67 to 7.20 ± 0.58 Ca2+ transients / 5 min (p=0.003). Additionally there was also a 
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slight increase in basal [Ca2+]i, from 0.00 ± 0.001 % of peak high-K
+ to 0.013 ± 0.02 % 
(p=0.018) (Figure 4.3.1.1). Importantly while there was an increase in the force produced by 
the tissue, this did not correlate with an increase in the amplitude of the Ca2+ transient 
which remained the same 75.24 ± 12.77 % of peak high-K+ in control vs 78.12 ± 13.76 %  in 
PGF2α (p=0.197). Ca
2+ spikes could be well resolved in 6 of the 7 spontaneous samples. The 
experiments showed that there was an increased in the frequency of Ca2+ spikes from 23.83 
± 4.73 spikes (measured during the initial 10 seconds) to 29.16 ± 6.43 spikes in the presence 
of PGF2α (p=0.038) (Figure 4.3.1.1a(iii)). This data suggest that the frequency of Ca
2+ spikes 
within the burst are responsible for the increase in force produced by PGF2α. 
In 5 samples, PGF2α caused a sustained rise in force from 61.66 ± 5.93 % of peak high-K
+ to 
90.53 ± 8.08 % (p=0.053), which remained elevated for the duration of PGF2α application. 
Again amplitude of the Ca2+ transient did not change being 100.63 ± 6.44 % of peak high-K+ 
in the absence and 97.15 ± 5.15 % in the presence of PGF2α (p=0.469). After removal of 
PGF2α tissue returned to control levels (Figure 4.3.1.2). 
As with previous results the data obtained suggests that the frequency of Ca2+ spikes are 
responsible for the increased production of force produced by PGF2α. 
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4.3.2     The effects of PGF2α on myometrial strips with irregular activity 
PGF2α increased force in spontaneously active phasic tissue by increasing the frequency and 
duration of Ca2+ bursts and the frequency of Ca2+ spikes within the burst. In tissue with 
irregular activity, PGF2α caused an increase in the amplitude and duration of contractions, 
while [Ca2+]i mirrored duration it did not show an increase in amplitude (Figure 4.3.2). From 
the expanded time scale shown in Figure 4.3.2b it is clearly seen that while there is no 
change in the amplitude of Ca2+ spikes there is an increase in the frequency of the Ca2+ 
spikes. It is this increase in frequency that is responsible for the increase in force seen with 
the addition of PGF2α, due to a more efficient summation of the individual phasic 
contractions. 
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4.3.3     The effects of PGF2α on quiescent myometrial tissue 
On quiescent tissue which was not spontaneously active but responsive to high-K+ 
stimulation, PGF2α caused the initiation of spontaneous phasic activity in 5 out of 6 strips 
tested. As with other tissue samples Ca2+ mirrored force in regards to duration and 
frequency, but again there was no change in the amplitude of Ca2+ spikes despite 
progressive increase in the amplitude of force seen in the presence of PGF2α (Figure 4.3.3). 
Upon removal of PGF2α, spontaneous activity was stopped and tissue strips were responsive 
only to high-K+ stimulation. 
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4.3.4     The effects of brief application of PGF2α are long lasting 
Agonist have different receptor binding characteristics, PGF2α has previously been shown to 
have a low dissociation constant (Coleman et al. 1994), it remains bound to its receptor for a 
long period before it will dissociate and stop exerting its effects. This can be clearly seen in 
figure 4.3.4, showing PGF2α response and washout period for spontaneous and quiescent 
tissue, respectively. Whilst the period of time taken for the tissue to return to pre-
application contractility profiles is varied, quiescent tissue was usually quickest to stop 
contracting, whilst tissue producing sustained contractions took the longest to return to 
control activity.  
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4.4     Discussion 
There are multiple myometrial agonists, all working to increase force, whether that be an 
increase in amplitude of force, duration, frequency or combination of all. PGF2α is not similar 
and in accordance with previous reports caused an increase in frequency, duration and 
amplitude of contractions (Reiner et al. 1976; Tuross et al. 1987; Beretta et al. 2004; 
Griffiths et al. 2006) which was seen in this study on uterine strips with three patterns of 
activity. 
There are multiple mechanisms by which uterine agonists increase myometrial contractility. 
It is generally agreed that agonists work through three principal mechanisms; 1) increase in 
the amplitude of [Ca2+]i above that seen during spontaneous activity (Molnar et al. 1990b) 2) 
depolarisation leading to an increase in frequency of action potentials and thus Ca2+ spikes 
(Burdyga et al. 2009) or 3) an increase in Ca2+ sensitisation, whereby there is an increase in 
the amount of force produced without a change in Ca2+ parameters (Izumi et al. 1996). 
Previous studies investigating the mechanisms of [Ca2+]i induced by PGF2α, reported that the 
effect is caused by an increase in [Ca2+]i, that is both intracellular- and extracellular- 
dependent (Kawarabayashi et al. 1997; Luckas et al. 1999; Ruttner et al. 2002). This 
correlates well with our observations seen in both spontaneously active and quiescent 
tissue. However, previous studies showed contradictory results to the effects of PGF2α on 
Ca2+ signalling. Two studies based on human myometrial tissue suggest an increase in the 
amplitude of the Ca2+ transient above that of spontaneous Ca2+ transients, was responsible 
for the increase in force (Molnar et al. 1990b; Parkington et al. 1999) while data obtained on 
rat longitudinal myometrial strips reported no change in [Ca2+]i, but an increase in basal 
[Ca2+]i during PGF2α response (Phillippe et al. 1997). This last study is what we see in rat 
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tissue, that while duration and frequency of Ca2+ transients correlate with force, the 
amplitude of [Ca2+]i does not change from that seen with spontaneous contractility, 
although there was an increase in basal [Ca2+]i, which correlated with the increase in basal 
force. The principal determining factors in the discrepancies between Ca2+ data may be due 
to technical errors, for example low sampling rate which will not allow Ca2+ signals to be 
accurately resolved or poor synchronisation between the muscle bundles within the strip 
(e.g. samples with irregular activity, see Figure 4.3.2 ) and / or movement artefacts present 
in large preparations which will affect the quality of the fluorescent signals. Fast confocal 
imaging of Fluo-4 loaded uterine strips was used to verify the temporal and saptail 
characteristics of the Ca2+ transients and correlate it with force. The data obtained strongly 
suggest that in well synchronised strips which show regular activity (e.g. Figure 3.3.1.3)  
there was a good correlation between the frequency of Ca2+ spikes and the amplitude of 
force with no change in the amplitude of the Ca2+ spikes. Electrophysiological experiments 
also showed that each spike was associated with a brief action potential of constant 
amplitude which again suggests that the amplitude of Ca2+ spikes is expected to be constant. 
The  mechanism of  Ca2+-induced Ca2+ release which could amplify a signal in uterine smooth 
muscle is is not present. Overall the data obtained strongly suggest that contraction of 
uterine strips is produced by a burst of action potential mediated Ca2+ spikes of constant 
amplitude which give rise to brief phasic contractions. Summation of these phasic 
contractions results in a bulid up of the complex tetanic-like phasic contraction similar to 
that seen in skeletal muscles. 
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It is clear from our data that whilst PGF2α does not increase the amplitude of Ca
2+ in rat 
myometria, it does result in an increase in the frequency of Ca2+ spikes within the burst of 
Ca2+ spikes. As previously described in chapter 3, in pregnant rat myometrium, each Ca2+ 
spike is associated with a single spike like action potential (Burdyga et al. 2009) and 
contractions consist of trains of action potentials which summate to increase force, were 
the higher the frequency of action potential the greater degree of force produced 
(Mironneau 1973). Based on this account of myometrial contraction, it can be extrapolated 
that the increase in Ca2+ spikes seen with PGF2α, is due to an increase in the frequency of 
action potentials. These data are in agreement with the electrophysiological observations of 
other agonists, which caused an increase in the frequency of action potentials within a burst 
(Kuriyama et al. 1976) and the frequency of bursts of action potentials (Lammers et al. 
1999), while inhibitory chemical such as histamine which cause uterine relaxation, reduced 
it (Blyth 1972). 
Whist there are contradictory opinions regarding [Ca2+]i  correlating with the amount of 
force produced by pregnant rat myometrial tissue, there is little dispute regarding the cause 
of the increase in frequency and duration of PGF2α induced contractility. PGF2α increased 
both frequency and duration of both the Ca2+ transient and phasic contractions, as seen 
previously (Phillippe et al. 1997). The production of force is directly correlated to the rise in 
[Ca2+]i,  with the duration and frequency of Ca
2+ transients correlating directly with the 
duration and frequency of force. [Ca2+]i  is linked with action potentials, with an influx of 
Ca2+ through VOCC responsible for the upstroke of the action potential (Shmigol et al. 
1998b) and so upon cessation of action potentials [Ca2+]i  falls, giving the relationship 
between the duration of the Ca2+ transient and action potential burst.  
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The single previous study of membrane potential induced by PGF2α on pregnant rat 
myometrium corroborates the relationship between force and [Ca2+]i, showing a slow 
depolarisation and an increase in both frequency and duration of action potential bursts 
(Osa et al. 1983) correlating with the increase in frequency and duration of Ca2+ transients 
and contractility seen in this study. 
In investigating the relationship between force and Ca2+ in smooth muscle, the role of Ca2+ 
sensitisation cannot be ignored. Other uterine agonists are known to work at least in some 
part through the effects of Ca2+ sensitisation (Izumi et al. 1996). While this study does 
suggest an increase in the frequency of Ca2+ spikes as the cause of increased force seen with 
PGF2α, it does not discount other contributory mechanisms, such as Ca
2+ sensitisation, or 
explain the mechanisms behind the increase in Ca2+ spikes. 
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Chapter 5 
 
How PGF2α affects force/Ca
2+ relationship in uterine smooth muscle 
 
 
5.1   Introduction 
The mechanisms by which PGF2α increase myometrial contractility has yet to be elucidated. 
From previous studies the importance of Ca2+ influx through VOCC and Ca2+ release from the 
SR have been suggested (Parkington et al. 1999; Coleman et al. 2000). Other mechanisms 
suggested to be involved include; modulation of the Na+/K+ ATPase activity (Parkington et al. 
1999), Ca2+ sensitisation (Izumi et al. 1996) and a reduction in cyclic [AMP] (Goureau et al. 
1990). 
The upstroke of action potentials and subsequent contraction in rat uterine smooth muscle 
is dependent upon the gradual depolarisation of the membrane until threshold activation of  
VOCC is reached, culminating in influx of Ca2+  (Shmigol et al. 1998b). Membrane potential is 
achieved through an unequal distribution of ions across the plasma membrane, which in 
uterine smooth muscle is primarily set through the electrochemical gradients of Na+, Cl-, K+ 
and Ca2+, maintained by the various channels, pump and transporters within the plasma 
membrane. Many agonists act to change the permeability of the plasma membrane by 
modulating one or more ion channels, transporters and pumps. For example a number of 
endogenous and exogenous ligands are able to exert their effects through BKCa channels. 
Both adenylyl cyclase (Okawa et al. 2000) and nitric oxide (Okawa et al. 1999) work through 
opening of the BKCa channels decreasing contractility, whilst oxytocin increases Cl
- current 
through ClCa channels, increasing contractility (Arnaudeau et al. 1994; Jones et al. 2004).  
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Another principal way in which agonists are able to increase myometrial output, is to 
release Ca2+ from the SR, as a result of GPCR PLC generated IP3. This mechanism is utilised 
by a number of agonists including; oxytocin (Molnar et al. 1995; Sanborn 1995), carbachol 
(Khac et al. 1996; Houdeau et al. 2005) and ATP (Gerwins et al. 1992). In addition to 
increasing [Ca2+]i, the depletion of the SR can lead to influx of Ca
2+, in a mechanism known 
as store operated Ca2+ entry (SOCE), thus further enhancing [Ca2+]i (Putney 2011). SOCE can 
be seen in the response of intracellular Ca2+ characteristics to agonists. SOCE has been 
associated with a secondary sustained rise in the [Ca2+]i in response to agonist (Wayman et 
al. 1996a; Wayman et al. 1996b; Parekh et al. 2005), while re-admittance of Ca2+ after 
agonist induced store depletion results in a sustained increase in basal [Ca2+]i  which is 
nifedipine resistant, discounting VOCC involvement, and can be induced by CPA and 
thapsigargin (SERCA inhibitors), discounting ROC involvement. These characteristics along 
with use of SOCE inhibitors have identified SOCE as a mechanism of action in many cell 
types, including uterine smooth muscle (Shlykov et al. 2003; Noble et al. 2009). Unlike other 
types of smooth muscle, SOCE has only recently been identified in the myometrium, and as 
such investigations are limited, although both oxytocin (Monga et al. 1999; Fu et al. 2000) 
and bradykinin (Wassdal et al. 1998) have been identified as possible agonists working 
through this mechanism in uterine smooth muscle. 
In addition to influx of Ca2+ through VOCC and SOCE, agonists have also been suggested to 
result in an influx of Ca2+ through ROC. ROC were identified in smooth muscle based on the 
inward Ca2+ current activated upon agonist stimulation. These currents are not voltage 
sensitive, like L-type Ca2+ channels (Murray et al. 1991) although they are also often not Ca2+ 
selective, and are frequently permeable to both Na+ and K+ (Benham 1989). Due to this lack 
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of selectivity, there is overlap between ROC and NSCC; channels activated in response to 
agonists which allow the passage of different ions (Shimamura et al. 1994; Miyoshi et al. 
2004). Confusion regarding the exact nature of ROC and NSCC has recently been 
exacerbated in smooth muscle, due to the discovery of SOCE. Many uterine agonists work 
by Ca2+ release from the SR, store depletion has been shown to result in the activation of 
both Ca2+ and non-selective inward currents (Hoth et al. 1993; Albert et al. 2003b; Parekh et 
al. 2005). It is not known whether the inward Ca2+- or non-selective currents induced by 
many myometrial agonists are due to direct coupling with ion channels, or involved with 
secondary messengers, such as DAG, which has been shown to directly activate a non-
selective inward current (Guinamard et al. 2004) or due to SOCE. 
Agonists rarely work by a single mechanism, oxytocin, perhaps the most studied myometrial 
stimulant, works through at least three mechanisms; 1) an increase in [Ca2+]i above resting 
levels (Anwer et al. 1989; Monga et al. 1996) 2) an increase in the frequency of action 
potentials (Taira et al. 1967; Osa et al. 1973) and 3) Ca2+ sensitisation (Tahara et al. 2002; 
Woodcock et al. 2004; Shmygol et al. 2006; Kawamata et al. 2007). Through its Gαq/11 
coupled-receptor, oxytocin activates PLC (Ku et al. 1995) resulting in an increase in both IP3 
and DAG (Shlykov et al. 2004; Sanborn et al. 2005). IP3 releases Ca
2+ from intracellular 
stores, while DAG has been associated with both Ca2+ sensitisation and Ca2+ influx through 
NSCC (TRP channels) (Shlykov et al. 2004), an inward current dependent on both Ca2+ and 
Na+ has been identified in response to oxytocin (Shimamura et al. 1994). In addition to 
increasing [Ca2+]i through store release, a portion of the increase in [Ca
2+]i upon oxytocin 
stimulation has been shown to be extracellular dependent, which cannot be accounted 
solely by the increase in Ca2+ flux through L-type Ca2+ channels (Sanborn et al. 1998). The 
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extra Ca2+ influx is thought to be through SOCE (Kawamata et al. 2007) although this has not 
been thoroughly investigated to date. 
PGF2α like oxytocin is a myometrial stimulant, working through its G-protein coupled 
receptor, as such it is likely that the mechanism by which it increases myometrial output is 
likely to be multifaceted. To date many mechanisms have been suggested, but not 
investigated fully; for this reason it was decided to investigate the involvement of some of 
the principal mechanisms of uterine agonists, primarily VOCC, ROC and NSCC in addition to 
the role of store release and subsequent SOCE.   
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5.2   Materials and methods 
 Tissue 
Longitudinal myometrial strips (1x2 mm) and isolated myocytes from the ovarian portion of 
22 day gestation Wistar rats were used throughout, obtained as described in Chapter 2. 
Simultaneous measurements of force and [Ca2+]i  
Simultaneous measurements of force and [Ca2+]i was achieved using a photometric system 
as previously described (see Chapter 2 for details). Tissue strips were continuously perfused 
with PSS or PSS 0Ca in the presence or absence of other reagents. Tissue was first left until 
stable contractility was achieved or tissue classified as quiescent. To determine if 
modulation of membrane potential was involved in the effects of PGF2α, PGF2α was applied 
to high-K+ (40mM KCl) contracting tissue. To investigate the involvement of VOCC, PGF2α 
was applied to tissue in the presence and absence of nifedipine (10µM). While store release 
was investigated by firstly maximally filling the SR by a brief (40s) application of high-K+ 
(40mM KCl), external Ca2+ removed (2mM EGTA) for 3 minutes followed by addition of 
agonist in the continuing absence of Ca2+. Ca2+ was then re-admitted into the external media 
and rebound parameters in the presence of nifedipine (10µM), and the SOCE inhibitors; La3+ 
(10µM) and Gd3+ (10µM) were analysed; using 20µM CPA as a positive control for SOCE. 
NSCC/ROC was studied using a combination of CPA (20µM) and nifedipine (10µM), to 
maximally activate SOCE and inhibit L-type VOCC. 
 Confocal measurement of [Ca2+]i 
To characterise PGF2α release from the store, confocal microscopy was used on both 
myometrial strips and isolated cells in the absence of external Ca2+. For both myometrial 
strips and isolated myocytes, high-K+ was applied briefly (40s) to fill the store, followed by 
128 
 
removal of external Ca2+ (2mM EGTA) and the addition of 5μM PGF2α in the continued 
absence of external Ca2+.  
 Analysis and statistics 
Application of PGF2α onto both high-K
+ and CPA induced contractions was analysed by 
measuring the peak amplitude of high-K+ / CPA response in the presence of PGF2α compared 
to the amplitude directly preceding agonist application, normalised to peak amplitude of 
initial high-K+ response, taken for 100 percent. A similar technique was used to determine 
the effects of inhibitors on PGF2α / CPA contracting tissue; amplitude of agonists was 
compared to amplitude after 2 minutes of inhibitor, expressed as a percentage of peak high-
K+, while amplitude of response to pre-treatment with nifedipine was compared to control 
experiment. 
Store release was measured from baseline at time of agonist application to peak response, 
expressed as a percentage of peak high-K+. Rebound amplitudes were taken 2 minutes after 
re-admittance of Ca2+ , or addition of nifedipine, with baseline taken at the time of Ca2+ re-
admittance, again expressed as a percentage of high-K+, and compared to appropriate 
control experiment. 
For confocal microscopy experiments the following temporal characteristics were 
measured; time to peak, the time taken from the beginning of Ca2+ rise to the front of Ca2+ 
peak, duration at 50% amplitude, half time of relaxation, the time for the Ca2+ transient to 
fall from the amplitude at 50% duration to 50% amplitude. The speed of propagation of Ca2+ 
wave was also analysed, the time taken for a Ca2+ wave to travel between two regions of 
interest over the distance between the two regions of interest. 
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Distribution of data was determined by use of Shapiro-Wilk test. Paired t-test or Wilcoxon-
signed rank test, or independent samples t-test or Mann-Whitney U test were used to 
determine significance, with significance set at p<0.05. Data is expressed as mean ± S.E.M. 
or median ± I.Q.R. as appropriate. 
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5.3   Results   
5.3.1   The effects of PGF2α on membrane potential 
In uterine smooth muscle, many agonist work by modulating membrane potential. 
Depolarisation of the membrane ensures that the maximum number of VOCC are open 
resulting in an influx of Ca2+, increasing [Ca2+]i, allowing for contraction. From preliminary 
unpublished data (Figure 5.3.1) (Burdyga, T.), it can be seen that PGF2α results in 
depolarisation and the initiation of a train of action potentials, the train of action potentials 
result in summation of phasic contractions (seen as notches in the force trace) associated 
with each action potential, increasing the total force. 
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5.3.2   The effects of PGF2α on partially depolarised tissue. 
To determine if PGF2α works through membrane depolarisation, PGF2α was applied during 
the tonic contraction induced by high-K+ (40mM KCl) induced partial depolarisation. 
Addition of 50nM PGF2α, a concentration previously shown to significantly increase force, 
resulted in no alteration in either the amplitude of contraction or [Ca2+]i; amplitude of the 
sustained component of high-K+ contraction was 72.48 ± 14.44 % of peak high-K+ compared 
to 82.27 ± 21.04 % (n=5, p=0.372) in the presence of PGF2α, and sustained level of [Ca
2+]i was 
67.96 ± 6.99 % of peak high-K+ and 69.29 ±  5.85 % respectively (n=5, p=0.374). In addition 
to no alteration in either force or amplitude of [Ca2+]i, the frequency of Ca
2+ spikes also 
remained the same (Figure 5.3.2a).  
When a higher concentration of PGF2α (5µM) was used, there was a transient increase in 
force and [Ca2+]i, with a cessation of Ca
2+ spikes (Figure 5.3.2b). Force increased from 70.22 
± 10.26 % of peak high-K+ to 122.80 ± 13.32 % (n=5, p=0.015), while [Ca2+]i increased from 
60.80 ± 8.55 % of peak high-K+ to 88.25 ± 8.98 % (n=5, p= 0.011) (Figure 5.3.2b).  
The discrepancy between the effects of 50nM and 5µM PGF2α can have two explanations; 
firstly the photometric apparatus was not sensitive enough to resolve small changes in 
[Ca2+]i induced by the lower concentration of PGF2α , or that the higher concentration of the 
agonist was able to recruit additional mechanisms of Ca2+ mobilisation. To ensure that all 
the effects of PGF2α are present, further investigations were achieved with use of a 
supramaximal concentration of 5μM PGF2α.  
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The increase in [Ca2+]i and force induced by PGF2α in partially depolarised tissue could be 
due to Ca2+ influx mediated by SOCE or entry through ROC/NSCC, in addition to release from 
the SR. 
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5.3.3   The effect of L-type VOCC inhibition. 
We have previously found that PGF2α resulted in an influx of Ca
2+ and the production of 
force. In order to investigate the possible contribution of plasma membrane ion channel 
enhancement of Ca2+ flux through VOCC we used nifedipine to inhibit L-type VOCC. 
Application of 10µM nifedipine inhibited high-K+ induced contractions in pregnant rat 
myometrial strips, confirming inhibition of L-type Ca2+ channels. Application of 
supramaximal concentration of PGF2α (5µM) in the continuing presence of nifedipine 
resulted in an increase in [Ca2+]i, and the production of force for the duration of treatment. 
Amplitude of force increased to 20.88 ± 27.98 % of peak high-K+ (n=5, p=0.005) and [Ca2+]i 
increased to 74.65 ± 20.68 % (n=5, p=0.005) (Figure 5.3.3.1), whilst there was an increase in 
[Ca2+]i, it is important to note that there were no Ca
2+ spikes within the Ca2+ transient, unlike 
during normal PGF2α response. 
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Similar to nifedipine pre-treatment, when L-type VOCC were inhibited during PGF2α induced 
contraction, there was a reduction in both force and [Ca2+]i, but neither were completely 
abolished. Force fell from 104.46 ± 12.34 % of peak high-K+ to 23.88 ±8.24 % (n=5, p=0.000), 
correlating to a 78.90 % reduction, while [Ca2+]i fell from 38.77 ± 7.89 % of peak high-K
+ to 
24.82 ±5.71 % (n=5, p=0.036), a 14.01 % reduction (Figure 5.3.3.2). Importantly to note as 
with the previous nifedipine experiment, inhibition of L-type Ca2+ channels again resulted in 
the abolishment of Ca2+ spikes. 
From these experiments it is clear that there is a voltage-independent Ca2+ entry resistant to 
nifedipine, increasing [Ca2+]i and producing force induced by PGF2α. 
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5.3.4   The effects of removal and re-admission of external Ca2+ on pregnant rat 
myometrium 
In order to investigate the possible role of SOCE, it is essential to establish the effects of 
removal and re-admission of external Ca2+ on uterine smooth muscle. Removal of external 
Ca2+ for both short term (5 minutes) and long term (15 minutes) in the presence of 2mM 
EGTA resulted in the cessation of Ca2+ transients and force production, whilst there was also 
a fall in basal [Ca2+]i. Upon re-admittance of Ca
2+,[Ca2+]i returned to normal levels and 
contractility profile returned to control levels (Figure 5.3.4). There was no overshoot of 
basal Ca2+ or force; basal [Ca2+]i of 0.8577 ± 0.009 A.U. to 0.8477 ± 0.009 A.U. (n=5, p=0.06), 
while force went from 0.065 ± 0.6 mN to 0.053 ± 0.16 mN (n=5, p=0.686). This suggests that 
the SR was not depleted by removal of external Ca2+ or the mechanism of Ca2+ release Ca2+ 
entry coupling is not present in rat uterine smooth muscle. 
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5.3.5   The effect of PGF2α in the absence of external Ca
2+ 
 To investigate the possibility that PGF2α is able to activate SOC, it must be able to deplete 
the store. High-K+ was first applied to the tissue to maximally fill the store and external Ca2+ 
removed in the presence of 2mM EGTA, PGF2α in the continuing absence of external Ca
2+ 
was applied in order to determine if agonists resulted in Ca2+ release from the store.   
Using the photometric system with 50nM F2α, a concentration that increases phasic 
contractility, there was no detectable increase in either [Ca2+]i or force production (n=5) 
(Figure 5.3.5.1(i)). However when 5µM PGF2α was applied [Ca
2+]i increased by 34.87 ± 18.83 
% of peak high-K+ (n=6, p=0.002) and force increase by 8.12 ± 6.86 % (n=6, p=0.002) 
(Figure5.3.5.1(ii)). As with previous experiments this failure to detect changes in either force 
of [Ca2+]i with 50nM PGF2α may be due to lack of sensitivity of the photometric system. To 
verify this the same protocol was implemented using confocal microscopy to measure [Ca2+]i 
in uterine strips. It can be clearly seen in figure 5.3.5.1(c) that 50nM PGF2α in the absence of 
external Ca2+, resulted in the oscillatory release of Ca2+ from the SR (n = 3), confirming that 
lack of changes in the photometric system are due to sensitivity levels, and so 5µM PGF2α 
was used in further experiments to study store release and SOCE using the photometric 
system. 
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Supramaximal concentration of PGF2α resulted in release of Ca
2+ from the store, increasing 
both [Ca2+]i and force (Figure 5.3.5.2(i)). This increase in force and [Ca
2+]i is also seen with 
other myometrial agonists known to cause SR Ca2+ release; Carbachol (CCh) resulted in an 
increase in force of 27.97 ± 43.34 % of peak high-K+ (n=5, p=0.003) and an increase in [Ca2+]i 
of 38.59 ± 18.72 % (n=5, p=0.002) (Figure 5.3.5.2 (ii)), while adenosine tri-phosphate (ATP) 
increased force to 14.41 ± 9.18 % of peak high-K+ (n=5, p=0.003), with an increase in [Ca2+]i 
to 72.78 ± 13.76 % of peak high-K+ (n=5, p=0.003) (Figure 5.3.5.2 (iii)). 
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To confirm Ca2+ release from the SR induced by PGF2α and to study its temporal 
characteristics confocal microscopy of isolated cells myocytes in the absence of external 
Ca2+ was performed (n = 11 cells, 5 animals). PGF2α resulted in the generation of Ca
2+ waves, 
which were initiated at one end of the cell and propagating to the other (Figure 5.3.5.3b). 
Ca2+ waves had the following characteristics; time to peak 1.07 s, duration 3.67 s and time 
to relaxation 1.59 s and a speed of propagation of 87.23 μm/s (Figure 5.3.5.3a).  
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5.3.6   The effects of L-type VOCC inhibition on sustained contraction induced by PGF2α 
and CPA  
PGF2α causes Ca
2+ release from the SR, but is it able to activate store-operated Ca2+ entry? A 
principal tool to investigate SOCE especially in smooth muscle is the SERCA inhibitor CPA, 
which has been previously used (Noble et al. 2009), and whose effects are not contaminated 
by ROC or downstream effects of PLC. In these and future experiments investigating SOCE, 
CPA is in the protocol or used as a comparison of the effects of PGF2α.  
Previous evidence has linked SOCE to a sustained raise in [Ca2+]i upon application of 
agonists. When L-type VOCC were inhibited (10µM nifedipine) during the sustained 
contraction of PGF2α, whilst there was a reduction in [Ca
2+]i and force, a significant 
proportion remained, immune to nifedipine. Basal force was maintained at 23.88 ± 4.12 % 
of peak high-K+ (n=5, p=0.044), and [Ca2+]i at 65.98 ± 3.46 % (n=5, p=0.001) (Figure 5.3.6(ii)). 
CPA like PGF2α also resulted in a sustained nifedipine resistant increase in force and [Ca
2+]i; 
force was maintained at 64.79 ± 12.18 % of peak high-K+ (n=5, p=0.005) and [Ca2+]i at 67.57 
± 10.58 % (n=5, p=0.005) (Figure 5.3.6 (i)). 
The maintenance of nifedipine resistant [Ca2+]i and force could be due to a number of 
factors, including; ROC, NSCC and SOCE. Comparison of response of PGF2α to CPA, suggests 
that it is probable that this response is due to SOCE, although further work is needed to 
confirm this. 
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5.3.7   The effects of re-admittance of external Ca2+ following PGF2α and CPA induced store 
depletion 
To investigate the rebound effects of store depletion by PGF2α on re-admittance of Ca
2+ to 
the external bathing solution, the store depletion protocol was extended. The SR was filled 
by high-K+ stimulation, Ca2+ removed from the external bathing solution in the presence of 
2mM EGTA, PGF2α (5µM) or CPA (20µM) was added in the continuing absence of Ca
2+ and 
following a short washout period Ca2+ was re-admitted to the external bathing solution. 
Re-admittance of Ca2+ after store depletion induced by PGF2α resulted in the initiation of 
spontaneous activity and an increase in both basal [Ca2+]i and force. [Ca
2+]i increased from 
37.73 ± 7.31 % of peak high-K+ in control experiments to 91.58 ± 13.78 % (n=6, p=0.007), 
while force also increased from 2.37 ± 0.72 % of peak high-K+ to 16.33 ± 2.80 % (n=6, 
p=0.003) (Figure 5.3.7.1). 
A similar response was seen when the store was depleted with CPA, upon re-admittance of 
Ca2+ spontaneous activity was initiated. Spontaneous activity which was phasic in all PGF2α 
samples, was only phasic in 2 out of the 6 samples tested with CPA, in the remaining 4 
samples response was tonic-like, until it returned to basal levels. As with PGF2α there was an 
enhanced basal [Ca2+]i and force. [Ca
2+]i increased from 37.73 ± 7.77 % of peak high-K
+  to 
74.25 ± 10.25 % (n=5, p=0.0018), while force increased from 2.37 ± 0.74 % of peak high-K+ to 
59.33 ± 8.87 % (n=5, p=0.001) (Figure 5.3.7.2). 
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5.3.8   The effects of L-type VOCC inhibition on rebound effect induced by PGF2α and CPA 
store depletion 
The enhanced rebound effect seen upon re-admittance of Ca2+ after store depletion by CPA 
can be due to a number of mechanisms; firstly by L-type Ca2+ channels, ROC/NSCC or by 
SOCE. To exclude L-type VOCC in the rebound effect of CPA and PGF2α, the L-type VOCC 
inhibitor, nifedipine (10µM) was added during the rebound phase. 
Inhibition of L-type VOCC had no effect on the rebound basal force or [Ca2+]i induced by 
PGF2α. Basal force in control experiments was 17.09 ± 4.47 % of peak high-K
+ compared to 
30.99 ± 7.77 % when L-type VOCC were inhibited (n=5, p=0.159), [Ca2+]i was 59.19 ± 55.22 % 
of peak high-K+ and 80.64 ± 57.63 % (n=5, p=0.078) (Figure 5.3.8.1). This was also the case 
for CPA induced rebound effects, with basal force remaining the same from 47.20 ± 6.55 % 
of peak high-K+ to 52.96 ± 11.98 % (n=5, p=0.685), while [Ca2+]i increased from 65.39 ± 6.91 
% of peak high-K+ to 111.24 ± 4.33 % (n=5, p=0.023) (Figure 5.3.8.2). The increase in [Ca2+]i  
with the addition of nifedipine onto CPA contracting tissue, is likely due to a slight change in 
temperature, to which rat uterine tissue is particularly sensitive and / or slight movement 
artifact during nifedipine treatment due to constraints within the methodology. In PGF2α 
experiemtns there was a trend increase in [Ca2+]i  although this did not reach significance. 
L-type VOCC do not play a role in the enhanced basal force and [Ca2+]i  seen with re-
admittance of Ca2+ after store depletion, although they are pivotal for the phasic activity 
seen. As CPA has similar response to that seen with PGF2α, which cannot be due to 
ROC/NSCC, this strongly suggests that the activation of Ca2+ entry following Ca2+ depletion of 
the store by both PGF2α and CPA is due to activation of SOCE. 
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 5.3.9   The effects of the SOCE inhibitors Gd3+ and La3+ on CPA rebound 
To confirm that the enhanced rebound effects seen with CPA in myometrial tissue is due to 
SOCE, the previous store depletion protocol was used in the presence of either La3+ or Gd3+; 
two non-specific inhibitors of SOCE. Both have been used extensively to study SOCE 
(Miyoshi et al. 2004; Noble et al. 2009).  
In the presence of La3+ basal force was substantially reduced, falling from 59.33 ± 8.87 % of 
peak high-K+ to 5.99 ± 2.63 % (n = 5, p = 0.001), which was not reflected in [Ca2+]i, from 
64.33 ± 16.95 % of peak high-K+ to 33.57 ± 27.56 % (n=5, p=0.890) (Figure 5.3.9(ii)). This was 
replicated with Gd3+; basal force falling from 59.33 ±8.87 % of peak high-K+ to 12.67 ± 4.03 % 
(n=5, p=0.007), which was also not reflected in [Ca2+]i. [Ca
2+]i remaining unchanged from 
74.25 ± 10.25 % if peak high-K+ to 68.06 ± 5.92 % (n=5, p=0.633) (Figure 5.3.9(iii)). In 
addition to the reduction in basal force, with the use of either inhibitor, the phasic 
contractility and concomitant Ca2+ transients seen in 2 of the 6 control strips was abolished. 
These experiments in part suggest that CPA works through SOCE in pregnant rat 
myometrium, in consensus with previously published data (Yang et al. 2002; Shlykov et al. 
2003; Noble et al. 2009). While SOCE was demonstrated by the reduction in enhanced basal 
force induced by the two inhibitors, it was not reflected in intracellular Ca2+ measurements. 
This lack of Ca2+ reduction in the presence of La3+ and Gd3+ is probably due to an inherent 
problem with the photometric measurement of [Ca2+]i. Large areas of tissue are measured 
in the photometric system and if tissue is not well synchronised, can lead to problems such 
as small Ca2+ transients, increasing levels of variation, this along with lack of sensitivity can 
result in erroneous non-significant results. Additionally both La3+ and Gd3+ are likely to affect 
Indo-1 fluorescence which could be one of the experimental pitfalls of using this indicator.  
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5.3.10   The effects of the SOCE inhibitors Gd3+ and La3+ on PGF2α rebound 
In order to determine if SOCE plays a part in the enhanced rebound effects seen with PGF2α, 
CPA SOCE inhibitor experiment was repeated in the presence of PGF2α. 
Similar to the effects of La3+ on CPA, both rebound force and [Ca2+]i induced by PGF2α was 
greatly reduced in the presence of the SOCE inhibitor, La3+ (Figure 5.3.10(ii)). Basal force fell 
from 16.33 ± 2.80 % of peak high- K+ to 5.10 ± 1.78 % (n=6, p=0.007), while [Ca2+]i also 
reflected this, falling from 91.58 ± 33.76 % of peak high-K+ to 39.17 ± 6.09 % (n=6, p=0.006).  
Unlike CPA rebound, La3+ did not inhibit phasic contractility induced by re-admission of Ca2+, 
although the length of contractility was significantly reduced.  
Unlike La3+, Gd3+ did not affect basal force of rebound induced by PGF2α store depletion. 
Basal force in control conditions was 16.33 ± 2.80 % of peak high-K+ compared to 22.31 ± 
7.13 % (n=5, p=0.479) in the presence of Gd3+. Although there was a reduction in basal 
[Ca2+]i, from 91.58 ± 13.78 % of peak high-K
+ in control conditions falling to 44.57 ± 8.50 % in 
the presence of Gd3+ (n=5, p=0.022) (Figure 5.3.10(iii)).   
From these results it is probable that PGF2α works to some extent through SOCE, La
3+ did 
result in a reduction in both basal force and [Ca2+]i although Gd
3+ did not reflect this 
reduction in force. This discrepancy could be due to a number of factors; firstly channels 
involved in SOCE are not equally sensitive to all inhibitors of SOCE, especially those of the 
TRP family (Jung et al. 2003; Beech 2005; Helli et al. 2005; McElroy et al. 2008). With some 
smooth muscles possessing Gd3+ insensitive SOCE (Wilson et al. 2002). To date store 
operated calcium channels have not been identified in pregnant rat myometrium, so while 
both inhibitors block rebound force for CPA, CPA and PGF2α may induced different subtype 
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of store operated Ca2+ channels. Secondly based on previous evidence (Coleman et al. 1994) 
and washout experiments (Chapter 3) PGF2α has low dissociation constant, and so this 
experiment will to a degree be contaminated with ROC/NSCC and the downstream effects. 
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5.3.11   The effects of PGF2α in the presence of CPA  
There are four possible Ca2+ entry mechanisms in uterine smooth muscle; L-type VOCC, 
SOCE, ROC and NSCC. Using the SERCA inhibitor CPA (20µM), the SR is depleted and the 
membrane is depolarised leading to the initiation of spike discharge followed by its 
depolarisation block (Figure 5.3.11.1) (Burdyga, T. Unpublished data). Addition of 5µM 
PGF2α in the presence of CPA resulted in an increase in both force and [Ca
2+]i; force 
increased from 127.83 ± 6.56 % of peak high-K+ to 151.29 ± 6.94 % (n=5, p=0.016), and 
[Ca2+]i from 40.52 ± 35.57 % of peak high-K
+ to 52.51 ± 41.90 % (n=5, p=0.046) (Figure 
5.3.11.2). 
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Whilst CPA will result in opening of L-type VOCC the addition of PGF2α may modulate the 
open probability, and so to ensure that L-type VOCC are not contributing to the increased 
force and [Ca2+]i seen with the addition of PGF2α, the L-type VOCC inhibitor nifedipine was 
applied in the presence of CPA. PGF2α resulted in an increase in force, from 47.08 ± 27.64 % 
of peak high-K+ to 65.27 ± 27.55 % (n=6, p=0.046), whilst there was no significant change in 
[Ca2+]i; from 92.93 ± 13.14 % of peak high-K
+ to 98.13 ± 15.49 % (n=6, p=0.349) (Figure 
5.3.11.3).   
Removal of external Ca2+ produced a quick relaxation of both [Ca2+]i and force induced by 
PGF2α  applied in the presence of combined application of CPA and nifedipine (Figure 
5.3.11.4). Force returning to an amplitude of 5.28 ± 1.73 % peak of high-K+, compared to 
pre-treatment levels of 3.24  ± 1.03 % (n=6, p=0.278). 
The fact that PGF2α can induce an increase in both [Ca
2+]i and force in the presence of CPA 
and an increase in force with the additional inhibition of L-type VOCC, lends support to the 
hypothesis that PGF2α works through ROC and NSCC. Although the lack of an increase in 
[Ca2+]i when L-type VOCC were inhibited suggests a failure in the sensitivity of the 
photometric system. NSCC play an important role in agonist response of smooth muscles, 
often with a Na+ current, further work is needed to establish both the role of NSCC and the 
currents involved. 
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5.4   Discussion 
Prostaglandin PGF2α like other myometrial agonists, exert their effects through multiple 
mechanisms. They are able to increase [Ca2+]i by release from the SR, which activates SOCE 
leading to the raised basal [Ca2+]i. It is also able to increase Ca
2+ influx through a presently 
unknown ROC/NSCC pathway. 
Preliminary evidence (Burdyga, T. unpublished) and previous work has shown that PGF2α 
caused gradual depolarisation of the cell membrane leading to the initiation of trains of APs 
(Osa et al. 1983). The addition of PGF2α resulted in a further increase in [Ca
2+]i and force 
when applied in high-K+ depolarised tissue, in agreement with previous work (Ruttner et al. 
2002). This increase in force and [Ca2+]i could be caused by numerous mechanisms including 
activation or modulation of one or multiple plasma membrane ion channels, resulting in 
depolarisation of the membrane and enhanced Ca2+ influx through L-type VOCC. Previous 
work has shown the dependence of the effects of PGF2α on external Ca
2+ (Parkington et al. 
1999; Coleman et al. 2000) however this is not the case, as PGF2α is able to increase both 
[Ca2+]i and force, when L-type VOCC are inhibited, as has been previously shown (Coleman 
et al. 2000). Whilst this cannot exclude the contribution of ion channel modulation of L-type 
VOCC, the degree of extra Ca2+ and force produced in the presence of nifedipine, and the 
lack of an increase [Ca2+]i with PGF2α highly suggests that other mechanisms are primarily 
responsible for the effects of PGF2α.  
One of the mechanism by which agonists increase myometrial contractility is by release of 
Ca2+ from the SR, occurring through the classical GPCR pathway. Briefly GPCR upon binding 
to its agonist activates PLC, resulting in an increase in IP3, releasing Ca
2+ from the SR 
(Berridge et al. 1984). This occurs for oxytocin (Molnar et al. 1995) ATP (Gerwins et al. 1992) 
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and carbachol (Khac et al. 1996; Houdeau et al. 2005).  PGF2α is also able to release Ca
2+ 
from the SR; in the absence of external Ca2+, PGF2α increased both [Ca
2+]i and force, which is 
in agreement with previous studies (Coleman et al. 1988; Coleman et al. 2000; Fu et al. 
2000). PGF2α presumably is able to do this using a mechanism similar to other agonists, 
including carbachol and ATP. Studies have shown that PGF2α results in a dose dependent 
increase in IP3. Unlike oxytocin, which is pertussis sensitive, PGF2α is not and so is likely to be 
coupled to Gq, which is in agreement with FP data (Maka et al. 1993; Phaneuf et al. 1993; 
Coleman et al. 1994).  
As PGF2α releases Ca
2+ from the store, it may be able to activate SOCE, allowing for a 
sustained influx of Ca2+ after depletion of the store. SOCE has been identified as an 
important mechanism of smooth muscle response to agonist in many tissue types; colonic 
(Kovac et al. 2008), cultured A10 cells (Xuan et al. 1992), coronary arteries (Wagner-Mann et 
al. 1992) and gallbladder myocytes (Morales et al. 2004), it has only recently been identified 
in myometrial smooth muscle, and studies are therefore limited (Wassdal et al. 1998; 
Shlykov et al. 2003; Noble et al. 2009; Murtazina et al. 2011). 
Evidence of SOCE in smooth muscle comes from the SERCA inhibitors CPA and thapsigargin, 
both are essential tools in the investigation of SOCE, as it depletes the store without 
contamination from other downstream effects of agonists, such as ROC, NSCC and Ca2+ 
sensitisation. Both CPA and thapsigargin have been shown to deplete the SR and activate 
SOCE (Wayman et al. 1996a; Wayman et al. 1996b; Wayman et al. 1999) and have both 
been shown not to directly activate SOCE, with SR depletion critical to the activation of 
SOCE (Albert et al. 2002; Beech et al. 2004). 
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It has previously been reported in rat uterine smooth muscle that depletion of the store by 
CPA resulted in an influx of Ca2+ through SOCE, which is sensitive to the SOCE inhibitors 
SKF96365 and La3+, while insensitive to nifedipine (Noble et al. 2009). The suggestion of 
SOCE in rat myometrial smooth muscle has been confirmed in this study, with the inhibition 
of L-type VOCC by nifedipine during CPA response there was a maintenance of both force 
and [Ca2+]i. There was also enhanced basal force and [Ca
2+]i after store depletion by CPA 
upon re-admittance of Ca2+ to the external solution. Both of these are highly suggestive of 
SOCE activity in uterine smooth muscle, due to the limited number of mechanisms that CPA 
can work through. The ability of the myometrium to operate through SOCE was further 
verified by the use of two non-specific SOCE inhibitors; La3+ and Gd3+   (Miyoshi et al. 2004; 
Noble et al. 2009) whereby enhanced rebound basal force was inhibited by both La3+ and  
Gd3+, but not by the L-type VOCC inhibitor nifedipine. 
While SOCE has been identified through [Ca2+]i and force measurements in myometrial 
smooth muscle, the currents involved have not been studied to date, due in part to the 
difficulties in measuring store operated currents in excitable cells. The nature of the current 
involved in SOCE in myometrial cells remains undetermined, whether it is Ca2+ specific or 
involves multiple ions, as both Ca2+ specific currents (ICRAC) and non-specific current (ISOC) 
have been identified in response to store depletion in a number of tissue types (Vaca et al. 
1994; Trepakova et al. 2000; Golovina et al. 2001; Albert et al. 2002). The identity of the 
channel or channels involved in SOCE in myometrial smooth muscle has also not been 
identified, but are likely to involve a heterogeneous group of ion channels. Studies have 
shown multiple proteins, mainly focusing on STIM, Orai and TRP family members, who are 
able to recreate both ICRAC and ISOC currents (Roos et al. 2005; Brueggemann et al. 2006; 
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Prakriya et al. 2006; Yeromin et al. 2006; Ambudkar et al. 2007). This heterogeneity in store 
operated channels may be responsible for the variation in the efficiency of SOCE inhibitors 
(Jung et al. 2003; Helli et al. 2005; McElroy et al. 2008) and their ability to block SOCE 
induced by different agonists (Murtazina et al. 2011).  
The ability of myometrial smooth muscle to activate SOCE through agonists has been 
studied, albeit in a limited way, primarily with oxytocin (Wassdal et al. 1998; Murtazina et al. 
2011) although other agonists such as bradykinin have been suggested to work through 
SOCE (Wassdal et al. 1998). Preliminary studies suggest both STIM, Orai and members of the 
TRP family are involved in the activation of SOCE in the myometrium (Shlykov et al. 2003; 
Murtazina et al. 2011). To date the ability of PGF2α to induce SOCE has not been 
investigated, the ability to study this phenomenon induced by PGF2α is made more difficult, 
due to its slow dissociation rate from its receptor (Coleman et al. 1994) and therefore long 
acting downstream effects, as shown in figure 4.3.4. This along with other mechanisms such 
as ROC, NSCC and Ca2+ sensitisation are responsible for the incomplete effects of La3+. 
Inhibition of SOCE by La3+ while resulting in a substantial reduction in the enhanced basal 
[Ca2+]i and force seen with PGF2α, did not completely abolish the response or stop the 
overlaying phasic contractility as seen with CPA, suggesting that other mechanisms are able 
to compensate partially if not fully for the effects of SOCE. These results suggest that while 
PGF2α does induce SOCE, it is only one of a number of mechanism by which PGF2α exerts it 
effects. In addition based on the lack of effects of Gd3+, it does may not do this by the same 
channel as CPA induced SOCE. 
As previously discussed it is difficult to separate SOCC from ROC and NSCC, but by utilising 
CPA and thapsigargin to empty the SR without activating receptors, the existence of such a 
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channel has been confirmed (Wayman et al. 1996a; Wayman et al. 1996b; Wallace et al. 
1999; Wayman et al. 1999; Albert et al. 2002). There is also evidence for the existence of 
ROC, whether it is a Ca2+ selective or a non-specific channel, which are independent of 
store-operated channels. Firstly and the most convincing data is that depletion of the SR 
does not inhibit subsequent activation by agonists (Wang et al. 1991; Guibert et al. 1999; 
Zholos et al. 2004) and secondly inhibition of IP3 receptors by heparin does not prevent ROC 
activation (Albert et al. 2003b).  
While experimental evidence has inferred their existence, little is known about ROC in 
smooth muscle, especially that of the myometrium. It is not known if receptors are directly 
coupled to the ion channel, or if the actions are a result of downstream effects of PLC, as 
PLC inhibitors suppress many ROC (Beech et al. 2004) while DAG has been shown to directly 
activate NSCC in rat cardiomyocytes (Guinamard et al. 2004). In addition to the poor 
understanding of ROC, information regarding ROC is further compounded by NSCC. There is 
evidence that agonists are able to activate non-specific currents and that ROC are often 
non-specific in smooth muscle (Shimamura et al. 1994; Ma et al. 2008), it has not been 
determined if these are two separate entities or if there is cross over between the two. Due 
to this confusion, in this present study the contribution of ROC/NSCC to the effects of PGF2α 
were not separated. When SOCE was maximally activated by CPA, PGF2α resulted in an 
increase in [Ca2+]i and force, although this statistical significance was not maintained when 
L-type VOCC was accounted for by nifedipine. As previously discussed this could have either 
been due to; a) the inherent problems of photometric measurements of [Ca2+]i and the 
degree of variation within the experiment, or b) Ca2+ sensitisation. There is one previous 
study which suggests ROC as a mechanism of action of prostaglandin in guinea-pig 
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myometrium, although the individual contributions of SOCE, ROC and NSCC were not 
identified (Coleman et al. 2000). There is also evidence that external Na+ is essential to the 
slow depolarisation phase of PGF2α induced depolarisation, onto which the spike-like action 
potential bursts are superimposed (Reiner et al. 1976), Ca2+ sensitisation has also been 
suggested to be involved in the response of PGF2α (Izumi et al. 1996; Woodcock et al. 2006). 
While this study suggests the importance of ROC/NSCC in the mechanism of PGF2α it is 
impossible at this time to determine the contribution of ROC/NSCC and the current involved 
in the effects of PGF2α. 
Whilst the evidence in this chapter is not conclusive, it strongly suggests that PGF2α works 
through multiple mechanisms, as seen with other uterotonics. SOCE, ROC/NSCC all 
individually contribute to the effects of PGF2α, working in conjunction to increase 
myometrial mechanical output. Further study is needed to establish the contribution of 
these mechanisms in addition to Ca2+ sensitisation. 
 
 
 
 
 
 
 
 
172 
 
 
 
 
 
 
 
 
Chapter 6 
Final discussion 
 
 
 
 
 
 
 
 
 
173 
 
Chapter 6 
Final discussion 
 
The aim of this work was to describe the relationship between force and [Ca2+]i in rat late 
gestation longitudinal myometrial strips and the effects of PGF2α on this relationship. The 
mechanism by which PGF2α exerts its affects was also investigated, primarily focused on the 
role of Ca2+ entry mechanisms.  
 
6.1   Force / Ca2+ relationship in pregnant rat uterine smooth muscle  
Three physiological contractility profiles were determined for rat myometrial tissue. Two 
were spontaneously active, the first and most prevalent of the spontaneous tissue, gave 
smooth phasic contractions of; 1.31 mN, 15 second duration and a frequency of 5 
contractions per minute. The second subset of spontaneously active tissue had irregular 
contractions, with contractions having a notched appearance and produced little force, with 
amplitude not reaching above 0.7 mN. The third and final contractility profile determined 
was quiescent; it was not spontaneously active but gave a normal contraction in response to 
high-K+ depolarisation. 
For all tissue, force mirrored Ca2+ transients, contractions were slightly preceded by a rise in 
[Ca2+]i, which remained raised for the duration of the contraction, falling before the 
relaxation phase. This rise in [Ca2+]i, was dependent on L-type VOCC, as inhibition with 
nifedipine resulted in abolishment of both spontaneous and high-K+ induced activity, while 
gap junctions were needed for appropriate signal propagation. 
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This is in concurrence with the current understanding of the control of rat myometrial 
contractility and can explain the three contractility profiles found in pregnant rat uterine 
smooth muscle. Myometrial contraction is Ca2+-dependent and is reliant upon the influx of 
Ca2+ through L-type VOCC, linked to the upstroke of action potentials (Shmigol et al. 1998b). 
When the slow wave of depolarisation reaches threshold potential for L-type VOCC, L-type 
VOCC open and the resulting influx of Ca2+, is sufficient to activate calmodulin leading to the 
downstream phosphorylation of MLC20 and the production of force (Kuriyama et al. 1976). 
In rat uterine smooth muscle, action potentials are spike like (Mironneau 1973) and the 
characteristic of the train of action potentials are responsible for both Ca2+ and force 
characteristics (Burdyga et al. 2009). 
The duration and frequency of myometrial contractions are modulated by action potentials. 
Modulation of membrane potential, alters the frequency that the threshold activation of L-
type VOCC are reached, thus altering the frequency of Ca2+ transients and therefore 
frequency of contractions. While the duration of contractions are directly linked to the 
duration of the Ca2+ transient. Force is determined by the frequency of action potentials 
with the burst, with an increase in the frequency of action potentials giving greater force, as 
a result of summation (Mironneau 1973). 
From this work in measuring simultaneous force and [Ca2+]i, it is clear that in understating 
the intimate relationship between membrane potential and Ca2+ parameters it is possible to 
infer information regarding membrane potential by monitoring changes in [Ca2+]i. Individual 
Ca2+ spikes within a Ca2+ transient are associated with single action potentials, with changes 
to the characteristics of bursts of action potentials, responsible for the change in Ca2+ 
characteristics and therefore force (Burdyga et al. 2009).  This was shown particularly clearly 
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in irregular activity in figure 3.3.1.2 were the relationship between individual Ca2+ spikes to 
individual notches in force can be clearly seen. While more evidence would be gained from 
measuring simultaneous force, [Ca2+]i and membrane potential, this is difficult and often 
impractical to do, but it is possible to infer information regarding membrane potential by 
monitoring changes in [Ca2+]i, although should be verified, by use of sucrose-gap 
simultaneous recording of electrical activity, Ca2+ and force. 
 
6.2   The effect of PGF2α on force /Ca
2+ relationship in pregnant rat uterine smooth muscle 
As with other uterotonics, PGF2α resulted in an increase in the amount of force produced by 
the tissue, occurring in three characteristic ways. On spontaneously active tissue, PGF2α had 
two responses; either increasing phasic activity, with an enhancement of both amplitude, 
duration and frequency or by inducing a sustained tonic-like contraction for the duration of 
agonist application. Meanwhile in quiescent tissue, PGF2α initiated spontaneous 
contractility. In all tissue types once PGF2α was withdraw, control parameters returned to 
the tissue after a lengthy washout period, suggesting a slow dissociation rate from the 
receptor, which has previously been described (Coleman et al. 1994). 
As previously described, there is an intimate relationship between membrane potential, 
Ca2+ transients and the production of force in uterine smooth muscle. Similar to 
spontaneous contractility, PGF2α induced contractions were preceded by a rise in [Ca
2+]i, this 
Ca2+ transient remained for the duration of the contraction and was responsible for the 
frequency of contractions. Unlike frequency and duration, there was no change in the 
amplitude of [Ca2+]i, with [Ca
2+]i amplitude for spontaneous contractions the same as those 
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induced by PGF2α, and so was not responsible for the increase in mechanical output seen 
with the addition of PGF2α. The amplitude of contractions, as previously described is 
controlled by the frequency of action potentials and therefore Ca2+ spikes within the burst 
(Mironneau 1973; Kuriyama et al. 1976; Lammers et al. 1999; Burdyga et al. 2009). This 
could be clearly seen with the addition of PGF2α onto spontaneously active tissue, were 
there was a significant increase in the frequency of Ca2+ spikes with the Ca2+ burst, 
correlating with the increase in force. In summary, from this work it can be concluded that it 
is the frequency of Ca2+ spikes with the Ca2+ burst is responsible for the amount of force 
produced in myometrial tissue, whether in spontaneous contractility or that induced by 
PGF2α. It is also probable that these Ca
2+ spikes are directly controlled by the frequency of 
action potentials. 
 
6.3   Mechanisms involved in the actions of PGF2α  
While the importance of PGF2α to myometrial contractility is in little doubt, little is known 
about its mechanism of action. Due to the importance of Ca2+ in the contractility of uterine 
smooth muscle, it was decided to investigate the three principal Ca2+ entry pathways 
activated in response to agonists in uterine smooth muscle; L-type VOCC, ROC/NSCC and 
SOCE. 
 
6.3.1 The role of L-type VOCC in the effects of PGF2α 
L-type VOCC play a pivotal role in both spontaneous and agonists induced contractility in 
pregnant rat myometrium, as they are responsible for the upstroke of the action potential. 
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A number of mechanism are able to modulate the Ca2+ influx through these channels in 
order to alter contractility (Brainard et al. 2007; Zhou et al. 2007). It is unlikely that F2α is one 
of the agonists which do this, as firstly there was no change in the amplitude of [Ca2+]i to 
reflect this, also inhibition of L-type VOCC by nifedipine did not prevent the increase in 
[Ca2+]i and force produced by PGF2α. In addition when L-type VOCC were inhibited during 
PGF2α induced contractions, while there was a significant reduction in both [Ca
2+]i and force, 
as would be expected due to the vital role of VOCC in any form of contraction in pregnant 
rat myometrium, a significant portion of both [Ca2+]i and force remained. Based on this 
study it can be suggested that while PGF2α does not modulate Ca
2+ influx through L-type 
VOCC, while it is impossible to fully discount any contribution towards the effects of PGF2α, 
the contribution is likely to be negligible. 
 
6.3.2   The role of ROC/NSCC in the effects of PGF2α 
ROC is the term coined for an ion channel permeable to Ca2+ that is activated upon binding 
of a ligand to its receptor; whether that be directly coupled to an ion channel, such as the 
P2X receptor (Fredholm et al. 1994), or by downstream effectors, such as DAG (Guinamard 
et al. 2004). The currents invoked are often non-selective, in addition to Ca2+ they are often 
also permeable to both Na+ and K+, but are not voltage-sensitive, and are not activated by 
store depletion (Wray 1993). Difficulties arise trying to differentiate between ROC and NSCC 
as ROC can be non-specific, like NSCC, while NSCC can be activated in response to agonist 
stimulation, in addition to being found in control conditions (Kuriyama et al. 1995; Miyoshi 
et al. 2004). For ease of investigation in this preliminary study of the involvement of ROC 
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and NSCC in the mechanism of PGF2α, ROC and NSCC were not differentiated and treated as 
one entity.  
CPA was used to determine if ROC/NSCC contribute to the effects of PGF2α. CPA inhibits the 
re-uptake of Ca2+ into the SR by SERCA, depleting the store, resulting in the activation of 
SOCE, as shown in this research and previously (Noble et al. 2009). In CPA contracting tissue, 
PGF2α caused a further increased in both [Ca
2+]i and force above that produced by CPA 
alone. This increase in[Ca2+]i and force could due to either ROC/NSCC. To discount the 
involvement of L-type VOCC, the inhibitor nifedipine was used. While the force remained 
significantly increased, [Ca2+]i was no longer significantly higher than CPA alone, although 
this was likely due to a lack of sensitivity in the photometric system. Further work is needed 
to ensure that this lack of significance is not due to the inherent lack of sensitivity of 
measuring [Ca2+]i by the photometric system. In order to determine the contribution of this 
pathway in the enhancement of force produced by PGF2α, electrophysiological techniques 
and further force Ca2+ experiments investigating the role of Na+ and other ions need to be 
completed. 
 
6.3.3   The role of Ca2+-release Ca2+-entry coupling in the effects of PGF2α 
SOCE was identified over a quarter of century ago, suggesting that a specific plasma 
membrane channel is activated upon agonist stimulated depletion of the SR, resulting in an 
influx of Ca2+ (Putney 2011). It has now been identified in many cell types; including many 
smooth muscles, but investigations of SOCE in uterine smooth muscle are limited. In this 
study CPA and the SOCE inhibitors La3+ and Gd3+ were used to determine that SOCE does 
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occur in late gestation rat myometrial smooth muscle, as previously suggested (Shimamura 
et al. 1994; Fu et al. 2000; Noble et al. 2009). 
Investigating SOCE induced by PGF2α is complicated by the slow dissociation of the agonists 
from its receptor, contaminating results. From this work there are a number of lines of 
evidence to suggest that PGF2α is able to induce SOCE. Critically like other myometrial 
agonists, PGF2α releases Ca
2+ from the SR, and so is a possible candidate for activating SOCE. 
In comparison with CPA, whose actions can only be due to SOCE, PGF2α also resulted in a 
sustained rise in basal [Ca2+]i and force when L-type VOCC were inhibited. Again similar to 
CPA there was a sustained enhanced rebound for both [Ca2+]i and force with the re-
admission of Ca2+ after store depletion, which was nifedipine insensitive, but attenuated 
with the SOCE inhibitor La3+. These results infer the existence of SOCE induced by PGF2α, 
further work is needed to elucidate the mechanism behind SOCE in uterine smooth muscle, 
and what current and channels are involved.  
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6.4   Future work 
The principal finding of this study was the identification of a significant release of Ca2+ from 
the SR, and a role for Ca2+ release Ca2+ entry coupling in the mechanism of PGF2α, primarily 
centred on SOCE, with the addition of Ca2+ influx through NSCC/ROC. It has left questions 
partially answered and opened up the possibilities of more mechanistic pathways in the 
involvement of PGF2α.  
This study has focused upon the Ca2+ influx pathways and store release, in response to 
PGF2α. The release of Ca
2+ from the SR in response of PGF2α will not be without effects; Ca
2+ 
can activate both K+ channels and Cl- channels, and agonists have been shown to modulate 
their function. Ca2+-activated K channels; BK, SK and IK can all be inhibited by TEA, and were 
shown not to be involved in the effects of PGF2α (data not shown). The role of ClCa channels 
has yet to be studied in response to PGF2α. It has previously been identified to increase 
contractility in response to oxytocin in uterine smooth muscle (Arnaudeau et al. 1994), and 
so may be an exciting mechanistic pathway for PGF2α to exert its effects. In order to 
establish if ClCa channels play a role in PGF2α stimulation, simultaneous force and Ca
2+ 
studies using the ClCa channel inhibitor, niflumic acid, in addition to patch clamp studies 
need to be completed. 
As previously discussed, Ca2+ sensitisation plays a role in agonist stimulation of uterine 
smooth muscle. Previous studies have suggested a role for Ca2+ sensitisation in the effects of 
PGF2α in the uterus (Izumi et al. 1996; Woodcock et al. 2006), although further work needs 
to be completed in order to verify this and to determine the mechanism by which this 
occurs.  In smooth muscle Ca2+ sensitisation occurs through modulation of either MLCP or 
MLCK, primarily through PKC or rho-kinase. Rho-kinase Ca2+ sensitisation occurring in 
181 
 
response to PGF2α in rabbit aorta (Ito et al. 2003). In order to establish if this is involved in 
the mechanism of PGF2α, the rho-kinase inhibitor H1152 and the PKC inhibitor Ro-32-0432 
and activator phorbol 12,13-dibutyrate (PDBu) in simultaneous force Ca2+ experiments 
would be completed. 
SOCE and ROCE/NSCE have been identified to play a role in the increased mechanical output 
produced by PGF2α, the way in which both SOCE and NSCC/ROC function in smooth muscle 
are currently unknown. The current PGF2α evokes through these pathways has not been 
identified in smooth muscle, presumably as a result of the difficulties in measuring small 
currents in excitable cells, were they can often be masked behind larger currents, and so 
difficult to isolate. Voltage-clamp studies on freshly isolated cells could be used to identify 
the currents induced by PGF2α, as it has previously been used to successfully identify a Na
+ 
and Ca2+ dependent inward current induced by oxytocin in freshly isolated pregnant rat 
myocytes (Shimamura et al. 1994). 
Identification of the channels involved in both SOCE and ROCE/NSCE, would be time 
consuming and difficult to achieve. A number of proteins have been proposed to form these 
channels. Perhaps the easiest to investigate would be STIM, which translocates to the PM 
upon activation (Zhang et al. 2005), and so immunohistochemistry techniques can be 
implemented in localise STIM in response to PGF2α. Orai and TRPCs have also been identified 
as possible SOCC and ROC/NSCC, use of RNAi introduced by reverse permeabilisation could 
be used to determine which proteins are involved in PGF2α induced contractility, this 
technique has previously been used to knock down protein in intact vascular tissue, without 
affecting contractility (Corteling et al. 2007; Baeyens et al. 2010). 
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Another interesting possibility for a mechanism of PGF2α is by increasing speed of 
propagation, by increasing interbundle communication. As shown in Chapter 3, gap 
junctions are pivotal to myometrial contractility, and have been shown previously to be 
modulated. There have been conflicting reports in regards to the modulation of gap 
junctions and prostaglandins (MacKenzie et al. 1983; Garfield et al. 1987), although no study 
has isolated PGF2α from other prostaglandins, or investigated spread of propagation. In 
order to determine if PGF2α influences gap junctions, confocal microscopy investigation of 
the temporal and spatial spread of Ca2+ through the tissue, along with simultaneous force 
recordings while inhibiting gap junctions the inhibitor 18-β-GA would need to be completed. 
In addition to this, to definitively exclude gap junctions from the cause of PGF2α’s effects, 
studies on isolated cells can be achieved using simultaneous electrophysiological, [Ca2+]i and 
contractility in response to PGF2α is possible. 
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6.5   Summary 
The broad aim of this study was to determine the force / Ca2+ relationship induced by PGF2α. 
In order to determine this, firstly the force / Ca2+ relationship in pregnant rat myometrial 
tissue needed to be understood. Three contractility patterns were found; a) quiescent, not 
spontaneously active, but responsive to high-K+ stimulation, b) spontaneous with irregular 
uncoordinated contractions, and c) spontaneous regular phasic contractions. Contractility 
was preceded by an increase in [Ca2+]i and the initiation of Ca
2+  spikes, which typically 
slowed before stopping, returning [Ca2+]i to basal levels. This increase in [Ca
2+]i was 
dependent upon L-type VOCC, with synchronisation dependent upon gap junction 
propagation of action potentials.  
PGF2α increased mechanical output of all tissue types, by increasing the frequency of Ca
2+ 
spikes within the Ca2+ burst. Quiescent tissue responded by the initiation of Ca2+ oscillations 
and concomitant force. While spontaneous tissue either resulted in an increase in phasic 
contractility or the production of a tonic-like contraction for the duration of agonist 
application.  
The mechanism by which PGF2α increases mechanical output is multifaceted. PGF2α caused 
oscillatory release of Ca2+ from the SR in the form of propagating Ca2+ waves initiated at one 
end of the cell. The release from the store was sufficient to activate SOCE, shown as a 
nifedipine resistant Ca2+ influx which was sensitive to La3+. In addition to the activation of 
SOCE, PGF2α also activated a ROC/NSCC influx. 
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